		Base	P30	P60

Brachial systolic blood pressure (mmHg)	Before	117 ± 13	116 ± 8	116 ± 8

After	117 ± 10	116 ± 11	119 ± 12

Brachial mean arterial blood pressure (mmHg)	Before	90 ± 10	92 ± 9	92 ± 9

After	91 ± 8	89 ± 9	92 ± 10

Brachial diastolic blood pressure (mmHg)	Before	73 ± 10	73 ± 9	71 ± 7

After	70 ± 8	71 ± 8	74 ± 9

Brachial pulse pressure (mmHg)	Before	44 ± 8	43 ± 7	45 ± 7

After	47 ± 7	45 ± 8	46 ± 8

Carotid systolic blood pressure (mmHg)	Before	109 ± 5	107 ± 3	107 ± 3

After	109 ± 4	106 ± 4	110 ± 4

Carotid pulse pressure (mmHg)	Before	37 ± 3	34 ± 2	36 ± 2

After	39 ± 3	35 ± 2	36 ± 3

Heart rate (bpm)	Before	58 ± 7	62 ± 5	60 ± 5

After	56 ± 6	60 ± 7a	60 ± 8

β‐stiffness (U)	Before	7.4 ± 3.9	6.6 ± 3.5	6.9 ± 4.0

After	6.2 ± 3.0b	5.6 ± 2.8a,b	6.2 ± 2.7

Brachial systolic blood pressure (mmHg)

Brachial mean arterial blood pressure (mmHg)

Brachial diastolic blood pressure (mmHg)

Brachial pulse pressure (mmHg)

Carotid systolic blood pressure (mmHg)

Carotid pulse pressure (mmHg)

Heart rate (bpm)

β‐stiffness (U)


Population	Genomic region	Number of windows	MinimumPperm	RefSeq genes

ID	Name	Cluster	Chr	Begin (bp)	End (bp)	Length (bp)

ITU	Telugu	A	10	132,953,074	133,048,305	95,232	189	0.013	TCERG1L

PJL	Punjabi	A	13	20,001,572	20,181,691	180,120	28	0.044	TPTE2


Component	M. indicus	R. oryzae

Biomass (g/L)	4.7 ± 0.2	4.0 ± 0.1

Biomass yield (g/g sugars consumed)	0.25 ± 0.01	0.28 ± 0.00

Protein 1	0.40 ± 0.01	0.51 ± 0.07

Total lipids 1	0.098 ± 0.011	0.044 ± 0.007

AIM 2 yield 1	0.31 ± 0.01	0.34 ± 0.01

Component

Biomass (g/L)

Biomass yield (g/g sugars consumed)

Protein 1

Total lipids 1

AIM 2 yield 1


Gene (total SNPs)	SNP	Minor allele frequency	BODE score	Post-BD FEV1	Maximum work	USCD SOBQ score


Date of DNA extraction	OTUs	Abundance (%)

17 July 2014	Aerococcus	14

Dermabacteraceae	12

Micrococcus	10

Enhydrobacter	9

Leuconostoc	6

Kocuria	6

Actinomyces	6

25 March 2015	Methylobacterium komagatae	65

Ruminococcaceae	11

Methylobacterium	6

26 March 2015	Methylobacterium komagatae	67

Methylobacterium	6


		Diabetic children	School children

Scale	No.items			F	d.f	p-value

		n	mean ± SD	α	n	mean ± SD

PedsQLTM 4.0 Generic

Core Scales

Child self-report

T	2	94	67.98 ± 14.	0		78.21+13	33	(	<


 	Number of patients	Percentage

OCD Group	135	75.4%

Non-OCD anxiety disorders group	44	24.6%


Rupintrivir concn (μM) at final passage or control treatment	Clone no.	Mean EC50 ± SDa (μM)	Fold change in sensitivityb	Amino acid substitution(s) in protease

20	1	14.3 ± 1.7	10.9	A105V/I109V

	2	12.3 ± 1.2	9.4	A105V/I109V

	3	15.3 ± 1.1	11.7	A105V/I109V

	1	8.5		A105V


Type	% Miss in positive	% Miss in random

All features	83%	85%

Gene expression	15–27%	24–43%

GO	39–66%	40–54%

Type	% Miss in positive

All features	83%

Gene expression	15–27%

GO	39–66%


Barriers to carrying out PU	Risk assessment number (%)	Documentation number (%)	Prevention number (%)

Total number of respondents	194 (100)	194 (100)	194 (100)

Lack of time	32 (23.7)	46 (34.1)	33 (24.4)

Unstable patient	17 (12.6)	16 (11.9)	24 (17.8)

Lack of training, resources, equipment, guidelines	26 (19.3)	0 (0)	22 (16.3)

Short staffed	33 (24.4)	30 (22.2)	20 (14.8)

Lack of knowledge	13 (9.6)	14 (10.4)	19 (14.1)

Lack of aids	0 (0)	15 (11.1)	14 (10.4)

Unable to assess	9 (6.7)	0 (0)	13 (9.6)

Problem with assessment tool	9 (6.7)	21 (15.6)	0 (0)

Forget	0 (0)	13 (9.6)	0 (0)

Lack of equipment	18 (13.3)	10 (7.4)	0 (0)

Patient un-cooperative/too ill	20 (14.8)	0 (0)	0 (0)

Barriers to carrying out PU	Risk assessment number (%)	Documentation number (%)

Total number of respondents	194 (100)	194 (100)

Lack of time	32 (23.7)	46 (34.1)

Unstable patient	17 (12.6)	16 (11.9)

Lack of training, resources, equipment, guidelines	26 (19.3)	0 (0)

Short staffed	33 (24.4)	30 (22.2)

Lack of knowledge	13 (9.6)	14 (10.4)

Lack of aids	0 (0)	15 (11.1)

Unable to assess	9 (6.7)	0 (0)

Problem with assessment tool	9 (6.7)	21 (15.6)

Forget	0 (0)	13 (9.6)

Lack of equipment	18 (13.3)	10 (7.4)

Patient un-cooperative/too ill	20 (14.8)	0 (0)


Label	Volume	t-value	Peak activation (LPI)

x	y	z

Left Thalamus	342	3.92	-9	6	12

Right Inferior Parietal Lobule	208	3.67	57	−57	39

Left Superior Medial Gyrus	184	3.65	3	36	42

Left Precuneus	179	3.59	3	−69	48

Right Middle Frontal Gyrus	137	3.64	33	15	60

Left Angular Gyrus	113	3.51	−57	−54	30

Left Middle Frontal Gyrus	96	3.69	−24	15	60

Left Middle Frontal Gyrus	90	3.48	−45	51	-3

Label	Volume	t-value	Peak activation (LPI)

x	y	z

Left Precuneus	179	3.59	3	−69	48

Right Middle Frontal Gyrus	137	3.64	33	15	60

Left Angular Gyrus	113	3.51	−57	−54	30

Left Middle Frontal Gyrus	96	3.69	−24	15	60

Left Middle Frontal Gyrus	90	3.48	−45	51	-3


Variables	Resource	Year	Operating institution

The number of general hospitals (per 100,000 persons)	Survey of Medical Institutions,	2002	Ministry of Health, Labor and welfare

The number of beds in hospital (per 100,000 persons)	Hospital Report	2002	Ministry of Health, Labor and welfare

Ratio of daily occupied beds in general hospital	Hospital Report	2002	Ministry of Health, Labor and welfare

The number of families in which the elderly were living alone (per 100 households with person 65 years or older)	Population Census	2002	Ministry of Public Management, Home Affairs, Posts and Telecommunications

Dwelling rooms (per dwelling)	Population Census	2002	Ministry of Public Management, Home Affairs, Posts and Telecommunications

Health service facilities for the elderly (per 100,000 persons 65 years old and over)	Survey of Institutions and Establishment for long-term care	2002	Ministry of Health, Labor and welfare


Data set name	Number of patients	Microarray type	Outcome

Chin [72]	130	Affymetrix GeneChip Human Genome U133A Array Set	Disease specific survival (Event = death from breast cancer)

Miller [73]	251	Affymetrix GeneChip Human Genome U133 Array Set	Disease specific survival (Event = death from breast cancer)

Pittman [74]	158	Affymetrix GeneChip Human Genome U95av2 Array Set	Overall survival (Even t = death from breast cancer)

Data set name	Number of patients	Microarray type	Outcome

Chin [72]	130	Affymetrix GeneChip Human Genome U133A Array Set	Disease specific survival (Event = death from breast cancer)

Miller 	2	Affymetrix GeneChip Human Genome	Disease specific survival (Event = death from breast c

Data set name	Number of patients	Microarray type	Outcome

[73]	51	 U133 Array Set	ancer)

Pittman [74]	158	Affymetrix GeneChip Human Genome U95av2 Array Set	Overall survival (Even t = death from breast cancer)


	B	Se

Intercept	0.23	0.16

Quality aspects:

 Total quality score	0.75	0.19

 Adjustment for confounders at study level	-2.34	0.81

 Culturally adjusted questionnaire	-1.83	0.52

Study characteristics:

 Country US	1.67	0.60

 Publication year	-0.00	0.04

 Adjustment confounders outcome level	-0.00	0.41

 Sample size majority reference group	0.00	0.00

 Sample size immigrant groups	-0.00	0.00

 Length of reference period of use	-0.15	0.26

 Background immigrant groups a

European	1.69	0.92

African	0.14	0.77

Asian	0.92	0.56

(South/central) American	0.23	0.60

Variance study levelb	0	0

Variance outcome level	0.92	0.09


Impact Category-	Group 1	Group 2	Group 3	Group 4	Group 5	Group 6

Non	0	0.2	0.215	0.212		0.


Sample no.	TDS (mg/L)	pH	Conductivity (Ds/m)

Before desalination	After desalination	Before desalination	After desalination	Before desalination	After desalination

Sample A-B	320	40	7.60	7.32	1	0.10


Strategy

Undiscounted

no-ART

ART

Discounted at 3%

no-ART

ART


	eGFR	Urinary protein	Systolic blood pressure

B*	p value	B*	p value	B*	p value

Complement system components

Complement C1q subcomponent subunit C	−	0.3	+	0.2	+	0.5

Complement C1r subcomponent	−	0.003	+	0.5	+	0.02

Complement C1s subcomponent	−	0.005	+	0.7	+	0.003

Complement C3	−	0.3	−	0.5	+	0.2

Complement C4-B	−	0.2	+	0.9	+	0.05

Complement C5	−	0.04	−	0.3	+	0.02

Complement C6	−	0.03	−	0.3	+	0.09

Complement C7	−	0.06	−	0.5	+	0.2

Complement C8 alpha chain	−	0.03	−	0.4	+	0.05

Complement C8 beta chain	−	0.02	−	0.2	+	0.004

Complement C8 gamma chain	−	0.1	+	0.6	+	0.4

Complement C9	−	0.01	−	0.24	+	0.01

Complement system regulators

Clusterin	−	0.02	−	0.3	+	0.1

Complement factor H	−	0.1	−	0.5	+	0.02

Complement factor H-related protein 1	−	0. 4	−	0.8	+	0.1

Complement factor H-related protein 2	+	0.9	−	0.9	+	0.5

Complement factor H-related protein 5	−	0.3	−	0.5	+	0.5

Complement receptor type 1	+	0.07	+	0.9	−	0.4

C4b-binding protein alpha chain	−	0.06	−	0.4	+	<0.001

	eGFR	Urinary protein	Systolic blood pressure

B*	p value	B*	p value	B*	p value

Complement system components

Complement C1q subcomponent subunit C	−	0.3	+	0.2	+	0.5

Complement C1r subcomponent	−	0.003	+	0.5	+	0.02

Complement C1s subcomp	−	0.0		0.	+	0.0

onent		05	+	7		03

Complement C3	−	0.3	−	0.5	+	0.2

Complement C4-B	−	0.2	+	0.9	+	0.05

Complement C5	−	0.04	−	0.3	+	0.02

Complement C6	−	0.03	−	0.3	+	0.09

Complement C7	−	0.06	−	0.5	+	0.2

Complement C8 alpha chain	−	0.03	−	0.4	+	0.05

Complement C8 beta chain	−	0.02	−	0.2	+	0.004

Complement C8 gamma chain	−	0.1	+	0.6	+	0.4

Complement C9	−	0.01	−	0.24	+	0.01

Complement system regulators

Clusterin	−	0.02	−	0.3	+	0.1

Complement factor H	−	0.1	−	0.5	+	0.02

Complement factor H-related protein 1	−	0. 4	−	0.8	+	0.1

Complement factor H-related protein 2	+	0.9	−	0.9	+	0.5

Complement factor H-related protein 5	−	0.3	−	0.5	+	0.5

Complement receptor type 1	+	0.07	+	0.9	−	0.4

C4b-binding protein alpha chain	−	0.06	−	0.4	+	<0.001


Phase	Normothermia	Hypothermia	Mortality

Male	Female	Male	Female	Total	n

1	23	20			7 (14%)	43

2	14	17	15	16	2 (3%)a	62

3	3	4	3	5	1 (6.25%)	15

Phase	Normothermia	Hypothermia	Mortality

Male	Female	Male	Female	Total	n

3	3	4	3	5	1 (6.25%)	15


	Skewed Distributions	Approximately Symmetric Distributions

Number of Factors	1	2	3	1	2	3

China	993	7	0	0	1000	0

India	62	938	0	0	932	18

Mexico	894	106	0	0	1000	0

Russian Federation	6	994	0	0	1000	0

South Africa	1000	0	0	0	396	604

Ghana	587	413	0	0	0	1000


	Time Between Ultrasound and MRI	PC VIPR Pressure (mmHg)	Ultrasound Pressure (mmHg)	Stenosis (%)

No Repair	7 days	16.3	42**	32.8

	5 months	32.3	33.8	26.2

	6 days	16.3	23.4	18.4

Post Repair	17 months	5.5	0*	11.1

	1 month	6.6	0*	6.9

	3 months	26.6	35.1	30.1

	2 years	-1.6	0*	24.8

	Time Between Ultrasound and MRI	PC VIPR Pressure (mmHg)	Ultrasound Pressure (mmHg)	Stenosis (%)

	2 years	-1.6	0*	24.8


	Training set (n = 86)	Validation set (n = 42)

Error rate (%)	9.1	16.7

Sensitivity (%)	97.5	93.3

Specificity (%)	74.8	58.3

AUC	0.93	0.89


Name	Function	Primer Sequence (5' to 3')	Tm (°C)	Product Length	Amplified Region

SIRT2	RT-PCR	CAACCTGGAGAAATACCGTCTT	61.0	166 bp	400–565

CAGTCCTTTTTCCTTCAGCAG

β-actin	Reference	CACCAACTGGGACGACAT	61.0	202 bp	320–521

ATACAGGGACAGCACAGC

RPS9	Reference	CCTCGACCAAGAGCTGAAG	61.0	64 bp	128–191

CCTCCAGACCTCACGTTTGTTC

GAPDH	Reference	CCAACGTGTCTGTTGTGGAT	61.0	80 bp	778–857

CTGCTTCACCACCTTCTTGA

Primer A	3'UTR region amplification	ACCCCTGACCTCACCAAAT	56.5	549 bp	19411–19959

GCACCTTTCAGCACTCTTC

Primer B	3'UTR region amplification	ACCCCTGACCTCACCAAAT	62.3	138 bp	19411–19548

CCTGTGGCCCCCTGAGCAGTTAGAGTCTAG

Name	Function	Primer Sequence (5' to 3')	Tm (°C)	Product Length	Amplified Region

RPS9	Reference	CCTCGACCAAGAGCTGAAG	61.0	64 bp	128–191

CCTCCAGACCTCACGTTTGTTC

GAPDH	Reference	CCAACGTGTCTGTTGTGGAT	61.0	80 bp	778–857

CTGCTTCACCACCTTCTTGA

Primer A	3'UTR region amplification	ACCCCTGACCTCACCAAAT	56.5	549 bp	19411–19959

GCACCTTTCAGCACTCTTC

Primer B	3'UTR region amplification	ACCCCTGACCTCACCAAAT	62.3	138 bp	19411–19548

CCTGTGGCCCCCTGAGCAGTTAGAGTCTAG


Data set name	Description

LIVER CANCER [46]	Microarrays: 181; Probes: 6,605; K = 2Samples and Class: 76 normal; 105 tumorConfiguration: (ngr = 8, ngc = 4, nsr = 27, nsc = 28)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=107

LYMPHOMA [47]	Microarrays: 81; Probes: 6,850; K = 3Samples and Class: 29 normal, 43 diffuse large B-cell lymphoma (DLBCL); 9 follicular lymphoma (FL)Configuration: (ngr = 4, ngc = 4, nsr = 24, nsc = 24); (ngr = 8, ngc = 4, nsr = 24, nsc = 24)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=79

RENAL CELL CARCINOMA [48]	Microarrays: 38; Probes: 13,608; K = 4Samples and Class: 3 normal; 26 clear cell carcinoma (CCC); 5 granular cell carcinoma (GCC);4 papillary carcinoma (PC)Configuration: (ngr = 8, ngc = 4, nsr = 27, nsc = 28)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=210

GASTRIC CARCINOMA [49]	Microarrays: 130; Probes: 15,541; K = 2Samples and Class : 28 normal; 102 tumorConfiguration: (ngr = 12, ngc = 4, nsr = 30, nsc = 32); (ngr = 12, ngc = 4, nsr = 29, nsc = 32); (ngr = 12, ngc = 4, nsr = 30, nsc = 30)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=232

LUNG CANCER [50]	Microarrays: 60; Probes: 20,601; K = 5Samples and Class: 6 normal; 35 adenocarcinoma (AC); 11 squamous cell carcinoma (SCC); 4 large cell lung cancer (LCLC); 4 small cell lung cancer (SCLC)Configuration: (ngr = 8, ngc = 4, nsr = 27, nsc = 28)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=100

Data set name	Description

LUNG CANCER [50]	Microarrays: 60; Probes: 20,601; K = 5Samples and Class: 6 normal; 35 adenocarcinoma (AC); 11 squamous cell carcinoma (SCC); 4 large cell lung cancer (LCLC); 4 small cell lung cancer (SCLC)Configuration: (ngr = 8, ngc = 4, nsr = 27, nsc = 28)http://genome-www5.stanford.edu/cgi-bin/publication/viewPublication.pl?pub_no=100


Clinical characteristics	LINE-1 methylation ratio by age and sex-adjusted


 	Ingenuity canonical pathways	p-value	Ratio	Molecules

A	TREM1 signaling	2.71 × 10-11	1.69 × 10-1	IL8, CXCL3, ICAM1, CD40, GRB2, IL10, TLR8, CASP1, IL1B, FCGR2B, NFKB1, TNF

 	Hepatic fibrosis/hepatic stellate cell activation	8.32 × 10-11	1.10 × 10-1	CXCL3, IL8, IL4R, CCR5, ICAM1, CD40, MYL6, IL10, IL6R, IL1B, IFNGR1, CCL5, NFKB1, TNF, CCR7, IL4

 	IL-10 signaling	3.82 × 10-9	1.41 × 10-1	TRAF6, SOCS3, FOS, IL4R, CCR5, MAPK14, IL10, IL1B, FCGR2B, NFKB1, TNF

 	IL-12 signaling and production in macrophages	6.87 × 10-9	8.97 × 10-2	IL10, MAF, IFNGR1, NFKB1, IRF1, TRAF6, FOS, MAPK14, CD40, ZNF668, NOS2, TNF, PRKD3, IL4

 	IL-17A signaling in gastric cells	3.33 × 10-8	2.80 × 10-1	IL8, FOS, MAPK14, CCL20, CCL5, NFKB1, TNF

B	Role of cytokines in mediating communication between immune cells	8.88 × 10-7	7.27 × 10-2	IL8, IFNB1, IL13, IL4

 	Communication between innate and adaptive immune cells	6.73 × 10-6	3.67 × 10-2	IL8, IFNB1, CCR7, IL4

 	Airway inflammation in asthma	1.81 × 10-5	3.33 × 10-1	IL13, IL4

 	Remodeling of epithelial adherens junctions	1.08 × 10-4	4.41 × 10-2	ACTR3, MAPRE1, CLIP1

 	Prolactin signaling	1.5 × 10-4	3.75 × 10-2	SOCS3, FOS, IRF1


	Univariable	Multivariable

	Odds ratio	Confidential interval	p value	Odds ratio	Confidential interval	p value

Age	0.98	0.95–1.03	0.63	1.02	0.96–1.10	0.49


Parameter	Total	With ≥ 2-year complete follow-up

Female	Male	Female	Male

Number of patients 	802	526	463	313

Number of knees	1069	716	574	397

Proportion right knees	51.7%	49.4%	51.4%	49.4%

Patient age, mean (range) years	71.9 (39–95)	70.9 (44–96)	73.3 (50–94)	71.6 (48–95)

Body mass index mean (range) kg/m2	33.2 (18–76)	32.3 (8–79)	32.6 (18–62)	32.0 (8–57)

Diagnosis

 Osteoarthritis	97.5%	98.6%	97.4%	98.7%

 Rheumatoid arthritis	1.6%	0.8%	1.9%	1.0%

 Avascular necrosis	0.6%	0.3%	0.4%	0.3%

 Osteonecrosis	0.1%	0.0%	0.2%	0.0%

 Posttraumatic arthritis	0.1%	0.1%	0.2%	0.0%

 Others	0.2%	0.1%	0.0%	0.0%

Length-of-stay, mean (range) days	2.5 (1–18)	2.2 (1–22)	2.4 (1–10)	2.1 (1–11)

Follow-up, mean (range) years	2.4 (0.7–7.2) 	2.4 (0.8–6.9)	2.9 (2–7.2)	2.9 (2–6.9)


Parameters	Negative control

Catalase	2.89 ± 0.11 (0.27)

Malondialdehyde	7.11 ± 0.30 (0.74)

Mucin content	0.52 ± 0.06 (0.15)

Nonprotein sulphhydryl concentration	2.31 ± 0.18 (0.45)

Superoxide dismutase	2.75 ± 0.35 (0.86)

Total protein content	342.5 ± 4.09 (10.03)

Ulcer index	10 ± 0.28 (0.70)


Time points	Bowel movement frequency, mean ± SD, episodes per wk	Stool consistency, mean ± SD, BSFS grade

PEG	PEG + PM	P	PEG	PEG + PM	P

Enrollment	2.5 ± 1.1	2.3 ± 0.7	0.344	2.6 ± 0.6	2.5 ± 0.7	0.395

2-week follow-up visit	5.9 ± 1.3	5.4 ± 1.4	0.168	4.2 ± 0.5	3.9 ± 1.0	0.271

4-week follow-up visit	6.3 ± 0.9	6.0 ± 1.2	0.659	4.4 ± 0.5	4.1 ± 0.6	0.267

8-week follow-up visit	6.3 ± 0.9	6.3 ± 1.0	0.924	4.2 ± 0.5	4.2 ± 0.5	0.857

Time points	Bowel movement frequency, mean ± SD, episodes per wk	Stool consistency, mean ± SD, BSFS grade

PEG	PEG + PM	P	PEG	PEG + PM	P

Enrollment	2.5 ± 1.1	2.3 ± 0.7	0.344	2.6 ± 0.6	2.5 ± 0.7	0.395

2-week follow-up visit	5.9 ± 1.3	5.4 ± 1.4	0.168	4.2 ± 0.5	3.9 ± 1.0	0.271

	6.3 ± 0.9	6.0 ±	0.6	4.4 	4.1 ±


Variants	AA change	Novel	Exon	Sift Prediction	Polyphen Prediction	MAF (%)

Score	Prediction	Score	Prediction	Control	PS	PSE

+21059 C/T	333A > T	Yes	5	0.28	Tolerated	0	Benign	0	0.5	0

+21029 C/G	323A > P	Yes	5	0.08	Tolerated	0.476	Possibly damaging	0.5	0	0

rs2296651	267S > F	No	4	0.31	Tolerated	0.88	Probably damaging	0.9	0.9	2.3

+18885 A/G	256 M > T	Yes	4	0	Damaging	0.839	Possibly damaging	0	0	0.5

+18131 A/G	222 L > S	Yes	3	0	Damaging	0.637	Possibly damaging	0	0	0.5

rs202213974	200 V > M	No	3	0	Damaging	0.819	Possibly damaging	0	0	0.5

+11121 G/C	131 L > V	Yes	2	0.23	Tolerated	0.484	Possibly damaging	0.5	0	0

rs148467625	88I > T	No	1	0.57	Tolerated	0.072	Benign	0.5	0.5	0


Original value	HNR-I	HNR-II	HNR-III	HNR-IV	HNR-V	HNR-VI	Total


							ICGA	FA

No.	Age	Sex	R/L	Cell/Flare	SRD	Optic disc hyperemia	Fuzzy choroidal vessels	Hypofluorescent dark dots	Pinpoints Hyperfluorescence	Pleocytosis

1	34	F	L	+	−	−	+	+	−	+

2	56	F	R	−	+	+	+	+	+	+

L	−	+	+	+	+	+

3	31	F	R	−	+	+	+	+	+	+

L	+	+	+	+	+	+

4	43	F	R	+	+	+	+	+	+	+

5	57	F	R	+	+	+	+	+	+	+

L	+	−	+	+	+	−

6	24	M	R	−	+	+	+	+	+	+

7	44	M	R	−	−	+	+	+	−	+

8	46	F	R	+	−	+	+	+	−	−

9	64	M	R	+	+	+	+	+	+	+

L	+	+	+	+	+	+

10	15	M	R	+	+	+	+	+	+	+

L	+	−	+	unknown	+	−


Supernatant	Colorimetric

1	3.8

2	13

3	12.3

4	2.2

5	12.7

6	10.6

7	0.9

8	14.8

9	3.9

d (average on difference)

sd (standard deviation of difference)

HPLC	Difference

3.3	0.5

12.7	0.3

11.7	0.6

3	−0.8

13.7	−1.0

11.2	−0.6

1.1	−0.2

13.9	0.9

3.9	0.0

d (average on difference)	0.03

sd (standard deviation of difference)	0.7


Potential operon (r value)	Gene ID	Putative or predicted function	Reference (s)

Iron uptake or heme synthesis

 yfeABCD operon* (r > 0.91)	YPO2439-2442	Transport/binding chelated iron	yfeABCD [54]

 hmuRSTUV operon (r > 0.90)	YPO0279-0283	Transport/binding hemin	hmuRSTUV [55]

 ysuJIHG* (r > 0.95)	YPO1529-1532	Iron uptake	-

 sufABCDS* (r > 0.90)	YPO2400-2404	Iron-regulated Fe-S cluster assembly?	-

 YPO1854-1856* (r > 0.97)	YPO1854-1856	Iron uptake or heme synthesis?	-

Sulfur metabolism

 tauABCD operon (r > 0.90)	YPO0182-0185	Transport/binding taurine	tauABCD [56]

 ssuEADCB operon (r > 0.97)	YPO3623-3627	Sulphur metabolism	ssu operon [57]

 cys operon (r > 0.92)	YPO3010-3015	Cysteine synthesis	-

 YPO1317-1319 (r > 0.97)	YPO1317-1319	Sulfur metabolism?	-

 YPO4109-4111 (r > 0.90)	YPO4109-4111	Sulfur metabolism?	-

Urea uptake and urease activation

 ure operon* (r > 0.96)	YPO2665-2672	Pathogenicity	ure [58, 59]

Stress response and adaptation

 dnaKJ operon (r = 0.97)	YPO0468-0469	Chaperones, chaperonins, heat shock	dnaKJ [60, 61]

 hslUV operon (r = 0.97)	YPO0105-0106	Adaptions and atypical conditions	hslUV [62]

 katY-cybCB operon* (r > 0.90)	YPO3319-3321	Detoxification and electron transport	-

 psp operon (r > 0.90)	YPO2349-2351	Adaptions and atypical conditions	psp operon [63]

Ribosome constituents

 rps-rpm-rpl operon (r > 0.90)	YPO0209-0235	Ribosomal protein synthesis and modification	rps-rpm-rpl operon [64]

Energy metabolism

 sdh-suc operon* (r > 0.92)	YPO1109-1116	Tricarboxylic acid cycle	sdhCDAB [65]

 cyo operon (r > 0.94)	YPO3164-3168	Aerobic respiration	cyoABCDE [55]

 nap operon (r > 0.94)	YPO3036-3040	Electron transport	nap operon [66]

 atp operon (r > 0.93)	YPO4120-4128	ATP-proton motive force	atpIBEFHAGDC [67]

 ace operon* (r > 0.90)	YPO3724-3726	Glyoxylate bypass	aceBAK [68]

 nuo operon* (r > 0.92)	YPO2543-2555	Aerobic respiration	nuo operon [69]

Degradation and transport/binding of amino acids

 pro operon* (r > 0.92)	YPO2645-2647	Transport/binding amino acids and amines	proVWX [70]

 ast operon (r > 0.90)	YPO1962-1966	Degradation of amino acids	astCADBE [71]

 gln operon* (r > 0.91)	YPO2512-2514	Transport/binding amino acids and amines	glnHPQ [72]

others

 YPO1994-1996* (r > 0.98)	YPO1994-1996	Unknown	-

 YPO0881-0884 (r = 0.99)	YPO0881-0884	Chemotaxis and mobility?	-

 YPO1087-1088 (r = 0.99)	YPO1087-1088	Phage-related functions and prophage	-

 YPO0623-0628* (r > 0.94)	YPO0623-0628	Unknown	-

 mur operon (r > 0.95)	YPO0550-0553	Murein sacculus and peptidoglycan	-

 idn operon (r = 0.96)	YPO2539-2540	Degradation of carbon compounds	-

 fad operon* (r = 0.95)	YPO3766-3767	Degradation of small molecule	-

 glg operon (r > 0.90)	YPO3938-3942	Synthesis and modification of cytoplasmic polysaccharides	glg operon [73]

 YPO3838-3839 (r = 0.92)	YPO3838-3839	Unknown	-

 YPO0408-0409* (r = 0.97)	YPO0408-0409	Unknown	-

 YPO1516-1517 (r = 0.90)	YPO1516-1517	Unknown	-

 YPCD1.15c-1.17c (r > 0.98)	YPCD1.15c-1.17c	Unknown	-

 yscGHIJK operon* (>0.90)	YPCD1.55-1.57	T3SS constituents	-

 YPPCP1.08c-1.09c (r = 0.97)	YPPCP1.08c-1.09c	Unknown	-

Potential operon (r value)	Gene ID	Putative or predicted function	Reference (s)

tauABCD operon (r > 0.90)	YPO0182-0185	Transport/binding taurine	tauABCD [56]

ssuEADCB operon (r > 0.97)	YPO3623-3627	Sulphur metabolism	ssu operon [57]

cys operon (r > 0.92)	YPO3010-3015	Cysteine synthesis	-

YPO1317-1319 (r > 0.97)	YPO1317-1319	Sulfur metabolism?	-

YPO4109-4111 (r > 0.90)	YPO4109-4111	Sulfur metabolism?	-

Urea uptake and urease activation

ure operon* (r > 0.96)	YPO2665-2672	Pathogenicity	ure [58, 59]

Stress response and adaptation

dnaKJ operon (r = 0.97)	YPO0468-0469	Chaperones, chaperonins, heat shock	dnaKJ [60, 61]

hslUV operon (r = 0.97)	YPO0105-0106	Adaptions and atypical conditions	hslUV [62]

katY-cybCB operon* (r > 0.90)	YPO3319-3321	Detoxification and electron transport	-

psp operon (r > 0.90)	YPO2349-2351	Adaptions and atypical conditions	psp operon [63]

Ribosome constituents

rps-rpm-rpl operon (r > 0.90)	YPO0209-0235	Ribosomal protein synthesis and modification	rps-rpm-rpl operon [64]

Energy metabolism

sdh-suc operon* (r > 0.92)	YPO1109-1116	Tricarboxylic acid cycle	sdhCDAB [65]

cyo operon (r > 0.94)	YPO3164-3168	Aerobic respiration	cyoABCDE [55]

nap operon (r > 0.94)	YPO3036-3040	Electron transport	nap operon [66]

atp operon (r > 0.93)	YPO4120-4128	ATP-proton motive force	atpIBEFHAGDC [67]

ace operon* (r > 0.90)	YPO3724-3726	Glyoxylate bypass	aceBAK [68]

nuo operon* (r > 0.92)	YPO2543-2555	Aerobic respiration	nuo operon [69]

Degradation and transport/binding of amino acids

pro operon* (r > 0.92)	YPO2645-2647	Transport/binding amino acids and amines	proVWX [70]

ast operon (r > 0.90)	YPO1962-1966	Degradation of amino acids	astCADBE [71]

gln operon* (r > 0.91)	YPO2512-2514	Transport/binding amino acids and amines	glnHPQ [72]

others

YPO1994-1996* (r > 0.98)	YPO1994-1996	Unknown	-

YPO0881-0884 (r = 0.99)	YPO0881-0884	Chemotaxis and mobility?	-

YPO1087-1088 (r = 0.99)	YPO1087-1088	Phage-related functions and prophage	-

YPO0623-0628* (r > 0.94)	YPO0623-0628	Unknown	-

mur operon (r > 0.95)	YPO0550-0553	Murein sacculus and peptidoglycan	-

idn operon (r = 0.96)	YPO2539-2540	Degradation of carbon compounds	-

fad operon* (r = 0.95)	YPO3766-3767	Degradation of small molecule	-

glg operon (r > 0.90)	YPO3938-3942	Synthesis and modification of cytoplasmic polysaccharides	glg operon [73]

YPO3838-3839 (r = 0.92)	YPO3838-3839	Unknown	-

YPO0408-0409* (r = 0.97)	YPO0408-0409	Unknown	-

YPO1516-1517 (r = 0.90)	YPO1516-1517	Unknown	-

YPCD1.15c-1.17c (r > 0.98)	YPCD1.15c-1.17c	Unknown	-

yscGHIJK operon* (>0.90)	YPCD1.55-1.57	T3SS constituents	-

YPPCP1.08c-1.09c (r = 0.97)	YPPCP1.08c-1.09c	Unknown	-


Variable	Male	Female	Overall

% active	95% CI	p value	% active	95% CI	p value	% active	95% CI	p value


Age Group		Boys	Girls

WC/Ht percentile	WC/Ht percentile


 	Actual positive	Actual negative

Predicted positive	TP	FP

Predicted negative	FN	TN


Clinical source	Total strains	ZOT positivity	Exotoxin 9 positivity	GSI	GSII

CD	29	72.41	72.41	10.34	89.66

Gastroenteritis	31	70.97	51.61	35.48	64.52

Lymphocytic colitis	1	100	100	0	100

Collagenous colitis	3	33.33	100	33.33	66.67

Bloody diarrhoea	8	100	37.5	50	50

Periodontal disease	1	100	100	100	0

Healthy	11	72.73	63.64	27.27	72.73

UC	4	25	50	50	50

All	88	71.59	60.22	28.41	71.59

Clinical source	Total strains	ZOT positivity	Exotoxin 9 positivity	GSI	GSII

CD	29	72.41	72.41	10.34	89.66

Gastroenteritis	31	70.97	51.61	35.48	64.52

Lymphocytic colitis	1	100	100	0	100

Collagenous colitis	3	33.33	100	33.33	66.67

Bloody diarrhoea	8	100	37.5	50	50

Periodontal disease	1	100	100	100	0

Healthy	11	72.73	63.64	27.27	72.73

			50	5	50


Anterior segment pathology	Number of eyes

Cornea diseases

 Mucopolysaccharidosis	4

 Keratoconus	3

Anterior segment congenital condition

 Mesoectodermal dysgenesis	2

 Sclerocornea	1

 Congenital glaucoma	2

 Microphthalmia	3

 Keratoglobus	1

Ocular trauma

 Self-sealing corneal penetrating injury	1

Anterior segment surgery

 Cornea transplant and glaucoma drainage tube	1

 Glaucoma drainage tube	1

Iridocorneal angle abnormalities

 Anterior synechiae post-uveitis	1

 Neovascular glaucoma	2

 Synechia associated to ciliary body lesion	1

Intermediate Uveitis	2

Ocular surface lesions

 Corneoscleral dermoid	1

Anterior segment pathology	Number of eyes

Iridocorneal angle abnormalities

Anterior synechiae post-uveitis	1

Neovascular glaucoma	2

Synechia associated to ciliary body lesion	1

Intermediate Uveitis	2

Ocular surface lesions

Corneoscleral dermoid	1


	Discussed with an HIV nurse practitioner	Discussed with an HIV care medical doctor	Discussed at the HIV care visit

	Never	Sometimes	Regularly	Never	Sometimes	Regularly	Never	Sometimes	Regularly

Topics that patients wanted to discuss	% (n)	% (n)	% (n)	% (n)	% (n)	% (n)	% (n)	% (n)	% (n)

STI-related symptoms	20 (12)	52 (30)	28 (16)	25 (15)	61 (36)	14 (8)	18 (11)	55 (33)	27 (16)

Information on STIs	24 (13)	48 (26)	28 (15)	23 (12)	57 (30)	21 (11)	13 (7)	52 (28)	35 (19)


Age	Discharge type	Single duct?	Initial surgery	Initial histology	Final histology	Treatment

32	Fresh blood	Yes	Micro	DCIS	Intermediate grade DCIS	Mx + ANS + recon

43	Fresh blood	No	TDE	DCIS	Extensive intermediate grade DCIS	Mx + ANS + recon

51	Fresh blood/serous	Yes	TDE	DCIS	High grade DCIS	Mx + ANS

58	Fresh blood	Yes	TDE	IDC	3 mm grade 3 IDC + extensive DCIS	Mx + ANC + recon

60	Fresh blood	Yes	Micro	DCIS	High grade DCIS	Mx + ANS

68	Fresh blood	Yes	TDE	IDC	3 mm grade 2 IDC + DCIS	Mx + ANC

69	Fresh blood	Yes	Micro	DCIS	Multifocal intermediate grade DCIS	Mx + ANS

72	History of fresh blood; serous discharge identified, dipstick +++ for blood	Yes	TDE	IDC	10 mm grade 2 IDC + DCIS	Mx+ ANC

74	Altered blood	Yes	TDE	IDC	10 mm grade 2 IDC + widespread DCIS	Mx and ANC

78	Fresh blood	Yes	TDE	DCIS	Multifocal intermediate grade DCIS	Simple Mx

88	Fresh blood	Yes	TDE	DCIS	Low grade DCIS	Simple Mx

Age	Discharge type	Single duct?

32	Fresh blood	Yes

43	Fresh blood	No

51	Fresh blood/serous	Yes

58	Fresh blood	Yes

60	Fresh blood	Yes

68	Fresh blood	Yes

69	Fresh blood	Yes

72	History of fresh blood; serous discharge identified, dipstick +++ for blood	Yes

74	Altered blood	Yes

78	Fresh blood	Yes

88	Fresh blood	Yes

Initial surgery	Initial histology	Final histology	Treatment

Micro	DCIS	Intermediate grade DCIS	Mx + ANS + recon

TDE	DCIS	Extensive intermediate grade DCIS	Mx + ANS + recon

TDE	DCIS	High grade DCIS	Mx + ANS

TDE	IDC	3 mm grade 3 IDC + extensive DCIS	Mx + ANC + recon

Micro	DCIS	High grade DCIS	Mx + ANS

TDE	IDC	3 mm grade 2 IDC + DCIS	Mx + ANC

Micro	DCIS	Multifocal intermediate grade DCIS	Mx + ANS

TDE	IDC	10 mm grade 2 IDC + DCIS	Mx+ ANC

TDE	IDC	10 mm grade 2 IDC + widespread DCIS	Mx and ANC

TDE	DCIS	Multifocal intermediate grade DCIS	Simple Mx

TDE	DCIS	Low grade DCIS	Simple Mx


	Nonretreatment Group B	Retreatment Group A

(N = 106)	(N = 125)

Age, years

 Mean (SD)	61.4 (10.00)	60.8 (10.39)

Gender, N (%)

 Female	62 (58.5)	74 (59.2)

 Male	44 (41.5)	51 (40.8)

Body mass index, kg/m2 (mean ± SD)	28.4 (4.06)	28.3 (4.05)

Kellgren-Lawrence Score - Study Knee [N (%)]

 Grade 1	11 (10.4)	10 (8.0)

 Grade 2	46 (43.4)	42 (33.6)

 Grade 3	49 (46.2)	73 (58.4)

WOMAC pain subscores - Study Knee (mean)	68.1	69.0


Subtype	OMIM ID	Causative gene	HGNC ID	Cytogenetic location	Inheritance

FHL1	267700	HPLH1a	HGNC:23824	9q21.3 - q22	AR

FHL2	603553	PRF1	HGNC:9360	10q22.1	AR

FHL3	608898	UNC13D	HGNC:23147	17q25.1	AR b

FHL4	603552	STX11	HGNC:11429	6q24.2	AR

FHL5	613101	STXBP2	HGNC:11445	19p13.2	AR b

XLP1	308240	SH2D1A	HGNC:10820	Xq25	XLR

XLP2	300635	XIAP	HGNC:592	Xq25	XLR

Subtype	OMIM ID	Causative gene	HGNC ID	Cytogenetic location	Inheritance

FHL2	603553	PRF1	HGNC:9360	10q22.1	AR

FHL3	608898	UNC13D	HGNC:23147	17q25.1	AR b

FHL4	603552	STX11	HGNC:11429	6q24.2	AR

FHL5	613101	STXBP2	HGNC:11445	19p13.2	AR b

XLP1	308240	SH2D1A	HGNC:10820	Xq25	XLR

XLP2	300635	XIAP	HGNC:592	Xq25	XLR


Clinical symptoms	PCNSL(NO of patients)	GBM(NO of patients)

Organic brain syndrome	22	12

Signs of intracranial hypertension	16	23

Paresis	16	19

Vertigo	12	13

Phatic disorder	11	14

Visual disturbances	7	3

Cranial nerve dysfunction other than visual disturbance	5	0

Fatigue	4	7

Dysesthesia or hypesthesia	4	1

Seizure	1	9


Description	Unit	n	Abbreviation

Milk yield	l/day	285	dMY

FMI per visit	kg/visit	13,908	vFMI

Feeding duration per visit	s/visit	13,908	vFdur

FMI (fresh matter intake)	kg/day	311	dFMI

Feeding time	min/day	311	dFtime

Feeding frequency	visits/day	311	dFfreq

Mean FMI per visit	kg/visit	311	mvFMI

Mean feeding duration per visit	s/visit	311	mvFdur

Daily feeding rate	g/min	311	dFR

Cow feeding rate	g/min	16	cFR

Rumination duration per event	min/event	7,697	eRUMdur

Rumination time	min/day	311	dRUMtime

Rumination frequency	events/day	311	dRUMfreq

Mean rumination duration	min/event	311	meRUMdur

Description	Unit

Milk yield	l/day

FMI per visit	kg/visit

Feeding duration per visit	s/visit

FMI (fresh matter intake)	kg/day

Feeding time	min/day

Feeding frequency	visits/day

Mean FMI per visit	kg/visit

Mean feeding duration per visit	s/visit

Daily feeding rate	g/min

Cow feeding rate	g/min

Rumination duration per event	min/event

Rumination time	min/day

Rumination frequency	events/day

Mean rumination duration	min/event

n	Abbreviation

285	dMY

13,908	vFMI

13,908	vFdur

311	dFMI

311	dFtime

311	dFfreq

311	mvFMI

311	mvFdur

311	dFR

16	cFR

7,697	eRUMdur

311	dRUMtime

311	dRUMfreq

311	meRUMdur


Downregulated Pathways	Fat	Liver	Muscle	Comments

Steroid Biosynthesis		Q; EQ		Target of Statins

Phagocytosis/ leukocyte extravasation	EQ			Innate Immune Response

EIF2 signaling			Q; EQ	Stress Response

Mitochondrial dysfunction			Q	Associated with disease

eIF4/p70S6K signaling			Q; EQ	Insulin Signaling

Oxidative phosphorylation			Q; EQ	Energy Production

PPARα/RXRα activation			Q	Gene Expression

Downregulated Pathways	Fat	Liver	Muscle	Comments

eIF4/p70S6K signaling			Q; EQ	Insulin Signaling

Oxidative phosphorylation			Q; EQ	Energy Production

PPARα/RXRα activation			Q	Gene Expression


	Termamyl

Parameter	Model (5) versus model (1)	Model (6) versus model (1)	Model (7) versus model (1)

vmax	t value = −2.874	t value = −3.214	t value = −3.327

P value = 0.045*	P value = 0.032*	P value = 0.029*

D.F. = 4	D.F. = 4	D.F. = 4

KM	t value = −1.921	t value = −1.873	t value = −1.683

P value = 0.127	P value = 0.134	P value = 0.168

D.F. = 4	D.F. = 4	D.F. = 4

	San Super

Parameter	Model (5) versus model (1)	Model (6) versus model (1)	Model (7) versus model (1)

vmax	t value = −2.582	t value = −2.053	t value = −3.179

P value = 0.061	P value = 0.109	P value = 0.033*

D.F. = 4	D.F. = 4	D.F. = 4

KM	t value = −1.982	t value = −1.895	t value = −1.778

P value = 0.118	P value = 0.131	P value = 0.150

D.F. = 4	D.F. = 4	D.F. = 4

	BAN

Parameter	Model (5) versus model (1)	Model (6) versus model (1)	Model (7) versus model (1)

vmax	t value = −2.301	t value = −2.182	t value = −2.089

P value = 0.083	P value = 0.094	P value = 0.105

D.F. = 4	D.F. = 4	D.F. = 4

KM	t value = −0.689	t value = −0.638	t value = −0.577

P value = 0.529	P value = 0.558	P value = 0.595

D.F. = 4	D.F. = 4	D.F. = 4

vmax	D.F. = 4	D.F. = 4	D.F. = 4

KM	t value = −1.982	t value = −1.895	t value = −1.778

P value = 0.118	P value = 0.131	P value = 0.150

D.F. = 4	D.F. = 4	D.F. = 4

	BAN

Parameter	Model (5) versus model (1)	Model (6) versus model (1)	Model (7) versus model (1)

vmax	t value = −2.301	t value = −2.182	t value = −2.089

P value = 0.083	P value = 0.094	P value = 0.105

D.F. = 4	D.F. = 4	D.F. = 4

KM	t value = −0.689	t value = −0.638	t value = −0.577

P value = 0.529	P value = 0.558	P value = 0.595

D.F. = 4	D.F. = 4	D.F. = 4


Health Care Providers

Unqualified providers (UQP)	Yes	Qualified Providers (QP)	Yes

n*	%	n	%

Village doctor	416	92.7	Public

Drug stores	341	75.9	Upazila Health Complex	136	30.3

Self-medication	302	67.3	Union Health/Satellite Clinic	100	22.3

FWA/FWV/Nurses	161	35.9	Private

Medical assistant	39	8.7	Private clinic	160	35.5

Homeopath	158	35.2	Paramedics	266	59.1

Spiritual treatment	94	20.9

Folk medicine	142	31.6

*n=number

Health Care Providers

Unqualified providers (UQP)	Yes	Qualified Providers (QP)	Yes

n*	%	n	%

Spiritual treatment	94	20.9

Folk medicine	142	31.6

*n=number


	No CAD (%) (n = 15)	CAD (%) (n = 38)

Hypertension (blood pressure > 140/90 mmHg or on antihypertensive therapy)	60	97

Increased abdominal circumference (male > 92 cm, females > 88 cm)	33.3	79.1

Abnormal glucose tolerance	0	55.26

Raised triglycerides (> 1.7 mmol/l)	26.7	50

Low HDL cholesterol (men < 1.0 mmol/l, women < 1.3 mmol/l)	33.33	42.10

Raised LDL cholesterol (> 3 mmol/l)	13.33	42.10

Cigarette smoking/previous smokers	20	62.5

Mean CIMT (mm)	0.998	1.13

Increased CIMT (> 0.8 mm)	53	76


(N = 24)	 Distance from the bladder neck	Distance from the echolucent urethral lumen

 	[mm]	% of urethral length	[mm]

Mean	19.43	64.9%	3.13

Median	19.00	64.5%	3.30

Std. dev.	3.19	6.9%	0.94


	Response options for doctors and researchersb

Benefit				Harm

A great deal	Quite a lot	Only a little	No benefit or harm	Only a little	Quite a lot	A great deal

Criteria for doctors and researchers

1. Significant discussiona or other intervention that presumably reduces other health care use	x

2. Need to contact child welfare	x

3. Some referrals to secondary care	x	x

4. Doctor’s role irreplaceable by nurse		x

5. Presumably reduced concernb		x

6. Some significant discussionsb		x

7. Nurse could have replaced the doctor			x

8. No significant harm as consequence of unhandled concerns			x

9. Suspicion that interaction failed or suspicion of no progress in care					x

10. The interaction failed or here was no progress in care						x

11. Suspicion of negative PREM or refusal of school doctor services in the future and no progress in care							x

PREM question

How much benefit or harm did you perceive from the school doctor’s health check?								I don’t know

Response options for parents	x	x	x	x	x	x	x	x

Response options for children		x	x	x	x	x

	Response options for doctors and researchersb

Benefit				Harm

A great deal	Quite a lot	Only a little	No benefit or harm	Only a little	Quite a lot	A great deal

Criteria for doctors and researchers

1. Significant discussiona or other intervention that presumably reduces other health care use	x

2. Need to contact child welfare	x

3. Some referrals to secondary care	x	x

4. Doctor’s role irreplaceable by nurse		x

5. Presumably reduced concernb		x

6. Some significant discussionsb		x

7. Nurse could have replaced the doctor			x

8. No significant harm as consequence of unhandled concerns			x

9. Suspicion that interaction failed or suspicion of no progress in care					x

10. The interaction fail						x

ed or here was no progress in care

11. Suspicion of negative PREM or refusal of school doctor services in the future and no progress in care							x

PREM question

How much benefit or harm did you perceive from the school doctor’s health check?								I don’t know

Response options for parents	x	x	x	x	x	x	x	x

Response options for children		x	x	x	x	x


Source	A lot	A fair amount	A little	Almost none

Chicago City Health Department	9.5	21.4	33.3	35.7

Chicago Housing Authority	9.5	14.3	23.8	52.4

Doctor	19.1	14.3	21.4	45.2

Friends and relatives	31.0	14.3	28.6	26.2

Illinois Department of Health	16.7	19.1	21.4	42.9

Newspaper	21.4	21.4	40.5	16.7

People for Community Recovery (PCR)	45.2	21.4	21.4	11.9

Private industry, such as Waste Management or Ford Motor Company	9.5	7.1	19.1	64.3

Radio	21.4	14.3	21.4	42.9

Television	31.0	28.6	33.3	7.1

U.S. Environmental Protection Agency	-	40.5	28.6	30.9

University/College scientists	4.8	26.2	33.3	35.7


Species	Whole wing	Red band

t	df	p	t	df	p

H. melpomene nanna	0.39	48.31	.70	−3.22	50.28	.002a


Appendix I: Key Economic Variables		Reference/Data Source

ECONOMIC

Annual Discount Rate	3%	27

Exchange Rate: Shekels to USD (2005)	4.35	12

Per capita GDP (USD 2003)	$16,497	12

Training Staff

Number of Clinics in Israel	3000	MOH Statistical Dept.

Staff per clinic receiving training	2	Ashkelon Project

Full Days Training in initial year	2	Ashkelon Project

Days training in subsequent years	1	Ashkelon Project

Cost per ticipant-day of training course	$100	Ashkelon Project

Tele-management & Operational costs per patient.	$60	Ashkelon Project

Nurse/GP guidance per patient in first year of program	$230	Ashkelon Project

Unit Care Costs

Ambulatory visit to Nurse or Nutritionist	$7.83	15 mins visit & 5 mins secretarial time

Ambulatory GP visit	$11.37	15 mins GP & 5 mins secretarial time

Cost of OPV	$99.14	25% of general hospital cost (30)

General Hospital Cost per day	$397	30

ICU cost per day	$1,586	estimated as four times general per diem cost (30)

Rehabilitation Hospital Cost per day	$238.85	30

Home Physiotherapy Visit	$38.53	30

Devices and Procedure costs

Stent	$202	Barzelai Hospital Accounts Dept.

Cypher	$2,989	Barzelai Hospital Accounts Dept.

Diagnostic Catheterisation	$2,464	30

Restenosis	$9,701	30, includes 1 day in ICU & 3 days in cardiac ward

Average cost of Catheterisation with Stent or cypher	$6,925	30

CABG operation	$12,740	30

TPA	$1,800	30 estimated as four times general per diem cost

PRS Streptokinaise	$81	31

Kidney Transplant Cost	$39,132	30

Haemodialysis cost	$313	30

Peritonea dialysis cost	$136	30

% receiving haemodialysis	88.8%	20

Average annual Dialysis Cost	$46,041	30

Drug Costs

Post-MI or stroke drugs per day per patient- Males	$1.92	14

Post-MI or stroke drugs per day per patient- Females	$1.79	14

Post-UAP drugs per day per patient- Males	$1.92	14

Post-UAP drugs per day per patient- Females	$1.79	14

Correct preventive medication per day	$0.92	14, Ace inhibitor, Aspirin & Statin

Inadequate preventive medication per day	$0.31	14, Assumed only 1 correct drug taken

Appendix I: Key Economic Variables

ECONOMIC

Annual Discount Rate	3%

Exchange Rate: Shekels to USD (2005)	4.35

Per capita GDP (USD 2003)	$16,497

Training Staff

Number of Clinics in Israel	3000

Staff per clinic receiving training	2

Full Days Training in initial year	2

Days training in subsequent years	1

Cost per ticipant-day of training course	$100

Tele-management & Operational costs per patient.	$60

Nurse/GP guidance per patient in first year of program	$230

Unit Care Costs

Ambulatory visit to Nurse or Nutritionist	$7.83

Ambulatory GP visit	$11.37

Cost of OPV	$99.14

General Hospital Cost per day	$397

ICU cost per day	$1,586

Rehabilitation Hospital Cost per day	$238.85

Home Physiotherapy Visit	$38.53

Devices and Procedure costs

Stent	$202

Cypher	$2,989

Diagnostic Catheterisation	$2,464

Restenosis	$9,701

Average cost of Catheterisation with Stent or cypher	$6,925

CABG operation	$12,740

TPA	$1,800

PRS Streptokinaise	$81

Kidney Transplant Cost	$39,132

Haemodialysis cost	$313

Peritonea dialysis cost	$136

% receiving haemodialysis	88.8%

Average annual Dialysis Cost	$46,041

Drug Costs

Post-MI or stroke drugs per day per patient- Males	$1.92

Post-MI or stroke drugs per day per patient- Females	$1.79

Post-UAP drugs per day per patient- Males	$1.92

Post-UAP drugs per day per patient- Females	$1.79

Correct preventive medication per day	$0.92

Inadequate preventive medication per day	$0.31

Reference/Data Source

27

12

12

MOH Statistical Dept.

Ashkelon Project

Ashkelon Project

Ashkelon Project

Ashkelon Project

Ashkelon Project

Ashkelon Project

15 mins visit & 5 mins secretarial time

15 mins GP & 5 mins secretarial time

25% of general hospital cost (30)

30

estimated as four times general per diem cost (30)

30

30

Barzelai Hospital Accounts Dept.

Barzelai Hospital Accounts Dept.

30

30, includes 1 day in ICU & 3 days in cardiac ward

30

30

30 estimated as four times general per diem cost

31

30

30

30

20

30

14

14

14

14

14, Ace inhibitor, Aspirin & Statin

14, Assumed only 1 correct drug taken


First author (public year) [Reference]	Experimental animal	Inoculum spores	Inoculation route	Outcome	Results

Kawai (2012) [2]	4-5-d old ddY mouse	Kudoa septempunctata	Oral	Bowel movements and FAR	Showing diarrheagenic activity (11/17) and significantly higher FAR

Ahn (2015) [6]	6-wk old BALB/c mice	Kudoa septempunc-tata	Oral	Bowl movements and histo-pathological examination	No significant diarrhea (0/32) and histopathologic changes (0/24)

Jang (2016) [7]	4-5-d old ddY mouse	Kudoa septempunc-tata	Oral	Bowel movements and FAR	No watery stool form (0/20) and no significant variations in FAR

Guo (2015) [8]	4-5-d old BALB/c suckling mice	Myxobolus hongh-uensis	Oral	Bowel movements, FAR, and histopathology	No significant change of FAR, no abnormal stool form (0/25) and no evidence of inflammation (0/25)

First author (public year) [Reference]	Experimental animal	Inoculum spores	Inoculation route	Outcome	Results

Kawai (2012) [2]	4-5-d old ddY mouse	Kudoa septempunctata	Oral	Bowel movements and FAR	Showing diarrheagenic activity (11/17) and significantly higher FAR

A	6-wk old BALB	K	Or	Bowl movements and histo	No significant diar

First author (public year) [Reference]	Experimental animal	Inoculum spores	Inoculation route	Outcome	Results

hn (2015) [6]	/c mice	udoa septempunc-tata	al	-pathological examination	rhea (0/32) and histopathologic changes (0/24)

Jang (2016) [7]	4-5-d old ddY mouse	Kudoa septempunc-tata	Oral	Bowel movements and FAR	No watery stool form (0/20) and no significant variations in FAR

Guo (2015) [8]	4-5-d old BALB/c suckling mice	Myxobolus hongh-uensis	Oral	Bowel movements, FAR, and histopathology	No significant change of FAR, no abnormal stool form (0/25) and no evidence of inflammation (0/25)


MIGS ID	Property	Term

MIGS-31	Finishing quality	High quality draft

MIGS-28	Libraries used	IonTorrent 100 bp and 400 bp single end reads

MIGS-29	Sequencing platforms	IonTorrent PGM

MIGS-31.2	Fold coverage	110×

MIGS-30	Assemblers	Newbler 2.6, MIRA 3.9.18, Sequencher 5.0.1

MIGS-32	Gene calling method	Prodigal

 	Locus Tag	M670

 	Genbank ID	JJRY00000000

 	Genbank Date of Release	2014-06-16

 	GOLD ID	Gi0050495

 	BIOPROJECT	PRJNA209301

 	Project relevance	Environmental, co-denitrification

MIGS 13	Source Material Identifier	LMG 28302

MIGS ID	Property	Term

MIGS-28	Libraries used	IonTorrent 100 bp and 400 bp single end reads

MIGS-29	Sequencing platforms	IonTorrent PGM

MIGS-31.2	Fold coverage	110×

MIGS-30	Assemblers	Newbler 2.6, MIRA 3.9.18, Sequencher 5.0.1

MIGS-32	Gene calling method	Prodigal

	Locus Tag	M670

	Genbank ID	JJRY00000000

	Genbank Date of Release	2014-06-16

	GOLD ID	Gi0050495

	BIOPROJECT	PRJNA209301

	Project relevance	Environmental, co-denitrification

MIGS 13	Source Material Identifier	LMG 28302


Clinicopathological features	GPx3 expression level (n)

Number	Down regulated	Non-down regulated	P

Sex				0.210

 Male	92	43	49

 Female	21	13	8

Age				0.926

 Younger than 55	57	28	29

 Older than 55	56	28	28

pTNM stagea				0.024 *

 Early stage (1-2)	29	9	20

 Advanced stage (3-4)	83	46	37

Venous infiltration				0.043 *

 Absent	47	18	29

 Present	66	38	28

Tumor sizea				0.462

 Less than 5 cm	47	25	22

 More than 5 cm	65	30	35

Tumor Nodulesa				0.448

 Less than 3	83	39	44

 More than 3	29	16	13

HBsAg				0.794

 Negative	13	6	7

 Positive	100	50	50

AFP levela				0.006 *

 Lower than 20 ng/mL	45	15	30

 Higher than 20 ng/mL	67	40	27

One year recurrencea				0.038*

 Recurrence	42	27	15

 Non-recurrence	62	27	35

Five year recurrencea				0.019*

 Recurrence	62	36	26

 Non-recurrence	43	15	28

Clinicopathological features	GPx3 expression level (n)

Number

Sex

Male	92

Female	21

Age

Younger than 55	57

Older than 55	56

pTNM stagea

Early stage (1-2)	29

Advanced stage (3-4)	83

Venous infiltration

Absent	47

Present	66

Tumor sizea

Less than 5 cm	47

More than 5 cm	65

Tumor Nodulesa

Less than 3	83

More than 3	29

HBsAg

Negative	13

Positive	100

AFP levela

Lower than 20 ng/mL	45

Higher than 20 ng/mL	67

One year recurrencea

Recurrence	42

Non-recurrence	62

Five year recurrencea

Recurrence	62

Non-recurrence	43


Medicine	MIC (mg/L)

AMPH-B	0.5

5-FC	<=0.12

MCZ	0.12

FLCZ	0.25

ITCZ	0.06

MCFG	0.12

VRCZ	<=0.015


Population	Frequency (%)	Number of subjects	Reference

African American	20	50	[48]

African American	36	85	[49]

African American	34	93	[152]

Tanzanians	36	95	[153]

Malawians	∧31 (15)	26	[60]

Ghanaians	46	42	[152]

Ghanaians	25	800	[78]

Ethiopians	∧45.5 (8.7)	262	[45]

Ivory coast	38	41	[152]

Sierra Leone	36	52	[152]

Senegal	60	10	[152]

Guinea	48	21	[152]

West Africa	42	166	[152]

West Africa	50	153	[49]

Yoruba (Ibadan, Nigeria)	35	78	[49]

South Africa	∧41 (23)	80	[154]

Xhosa (South Africa)	∧∧17	109	[155]

CMA (South Africa)	∧∧9	67	[155]

Botswana	36.6	101	[156]

Zimbabwe	49	71	[76]

Uganda	35.6	121	[63]

Uganda	29	7 males	[13]

Mozambique	7	78	[14]


Cultivar	TDZ/BA concentration	No. of explants	% of explants producing massive shoots/budsx(mean ± standard error)

Accent Red	1 μM TDZ + 0 μM BA (IM1)	121	20.5 ± 6.4 A

	2.3 μM TDZ + 1.8 μM BA (IM2)	121	66.5 ± 6.4 B

	1 μM TDZ + 2.2 μM BA (IM3)	119	42.6 ± 6.4 C

Salmon	1 μM TDZ + 0 μM BA (IM1)	65	59.5 ± 5.3 A

Picote	2.3 μM TDZ + 1.8 μM BA (IM2)	68	80.1 ± 4.6 B

	1 μM TDZ + 2.2 μM BA (IM3)	65	43.9 ± 5.3 A


The Value of L (mm)	Strength of the Alternating Magnetic Field (A/m)	Compensation Ratio of Vpp	fL (kHz)	fn(kHz)	Relative Tolerance

20	6892	1.11	-	172	-

25	7299	1.05	160	138	13.7%

30	7499	1.02	140	115	17.8%

40	7651	1	100	86	14%

The Value of L (mm)	Strength of the Alternating Magnetic Field (A/m)	Compensation Ratio of Vpp	fL (kHz)	fn(kHz)	Relative Tolerance

30	7499	1.02	140	115	17.8%

40	7651	1	100	86	14%


Manner of intent a,b	Total N (%)	Mean	Std. Dev.	Min	Max

Total firearm deaths	5,660 (100)	138.1	43.5	67	243

 Accidental	164 (2.9)	4	3.2	-	11

 Suicide a	5,025 (88.8)	122.6	40	57	212

 Homicide a	432 (7.6)	10.5	4.7	2	24

 Event of undetermined intent a	34 (0.6)	0.8	0.9	-	3

 Legal investigation.	- (-)	-	-	-	-

 Operation of war c	5 (0.1)	0.1	0.3	-	1

MALE

Total firearm deaths	5,334 (100)	130.1	40.2	64	221

 Accidental	158 (3.0)	3.9	3.1	-	11

 Suicide a	4,863 (91.2)	118.6	37.9	54	199

 Homicide a	276 (5,2)	6.7	3.6	1	15

 Event of undetermined intent a	32 (0.6)	0.8	0.9	-	3

 Legal investigation	- (-)	-	-	-	-

 Operation of war c	5 (0.1)	0.1	0.3	-	1

FEMALE

Total firearm deaths	326 (100)	8	4.1	1	22

 Accidental	6 (1.8)	0.2	0.4	-	1

 Suicide a	162 (49.7)	4	2.7	-	13

 Homicide a	156 (47.9)	3.8	2.3	-	10

 Event of undetermined intent a	2 (0.6)	0.1	0.2	-	1

 Legal investigation	- (-)	-	-	-	-

 Operation of war c	- (-)	-	-	-	-

Manner of intent a,b	Total N (%)	Mean	Std. Dev.	Min	Max

Suicide a	4,863 (91.2)	118.6	37.9	54	199

Homicide a	276 (5,2)	6.7	3.6	1	15

Event of undetermined intent a	32 (0.6)	0.8	0.9	-	3

Legal investigation	- (-)	-	-	-	-

Operation of war c	5 (0.1)	0.1	0.3	-	1

FEMALE

Total firearm deaths	326 (100)	8	4.1	1	22

Accidental	6 (1.8)	0.2	0.4	-	1

Suicide a	162 (49.7)	4	2.7	-	13

Homicide a	156 (47.9)	3.8	2.3	-	10

Event of undetermined intent a	2 (0.6)	0.1	0.2	-	1

Legal investigation	- (-)	-	-	-	-

Operation of war c	- (-)	-	-	-	-


Variable	Premetformin	Postmetformin	Change	P-value


Gene Description	Unigene	Gene Bank	Function

Cadherin 5, type 2, VE-cadherin	Hs.76206	NM_001795	Plays an important role in cell adhesion and is crucial for vessel growth and maturation.

Collagen, type XVIII, alpha 1	Hs.517356	NM_030582	Component of extra-cellular matrix (ECM) that is important for tissue organization.

Collagen, type IV, alpha 3	Hs.570065	NM_000091

Integrin, alpha V	Hs.436873	NM_002210	Cell adhesion molecules that plays a key role in tumor growth, angiogenesis and metastasis.

Integrin, beta 3	Hs.218040	NM_000212

Hepatocyte growth factor	Hs.396530	NM_000601	Stimulates tumor cell motility, invasion and angiogenesis and its receptor is a tyrosine kinase encoded by c-met.

Ephrin-A3	Hs.516656	NM_004952	Ephrins are cell-membrane-bound ligands for Eph receptor tyrosine kinases and regulate a variety of developmental processes.

Platelet-derived growth factor alpha polypeptide	Hs.645488	NM_002607	Stimulates endothelial cell proliferation.

Epidermal growth factor	Hs.419815	NM_001963	An EGFR ligand, regulates cell growth, proliferation and differentiation.

Neuropilin 2	Hs.471200	NM_003872	Receptor for VEGF and semaphorin (SEMA) and is involved in angiogenesis and neuronal guidance.

Ephrin-B2	Hs.149239	NM_004093	An Eph ligand, promotes cell attachment, cell-adhesion, migration, capillary tube formation and tumor angiogenesis.

Jagged 1	Hs.224012	NM_000214	A notch ligand, it regulates a transmembrane ligand-receptor signaling pathway involved in the regulation of endothelial cell differentiation.

Tumor necrosis factor, alpha-induced protein 2	Hs.525607	NM_006291	A cytokine mainly produced by macrophages causes apoptotic cell death, cellular proliferation, differentiation and inflammation.

TEK tyrosine kinase, endothelial	Hs.89640	NM_000459	Helps in vascular maturation, maintenance of integrity and remodeling.

Transforming growth factor, alpha	Hs.170009	NM_003236	Binds to EGFR and is involved in tumorigenesis.

Vascular endothelial growth factor C	Hs.435215	NM_005429	Involved in angiogenesis and lymphangiogenesis.

Gene Description	Unigene	Gene Bank	Function

Collagen, type IV, alpha 3	Hs.570065	NM_000091

Integrin, alpha V	Hs.436873	NM_002210	Cell adhesion molecules that plays a key role in tumor growth, angiogenesis and metastasis.

Integrin, beta 3	Hs.218040	NM_000212

Hepatocyte growth factor	Hs.396530	NM_000601	Stimulates tumor cell motility, invasion and angiogenesis and its receptor is a tyrosine kinase encoded by c-met.

Ephrin-A3	Hs.516656	NM_004952	Ephrins are cell-membrane-bound ligands for Eph receptor tyrosine kinases and regulate a variety of developmental processes.

Platelet-derived growth factor alpha polypeptide	Hs.645488	NM_002607	Stimulates endothelial cell proliferation.

Epidermal growth factor	Hs.419815	NM_001963	An EGFR ligand, regulates cell growth, proliferation and differentiation.

Neuropilin 2	Hs.471200	NM_003872	Receptor for VEGF and semaphorin (SEMA) and is involved in angiogenesis and neuronal guidance.

Ephrin-B2	Hs.149239	NM_004093	An Eph ligand, promotes cell attachment, cell-adhesion, migration, capillary tube formation and tumor angiogenesis.

Jagged 1	Hs.224012	NM_000214	A notch ligand, it regulates a transmembrane ligand-receptor signaling pathway involved in the regulation of endothelial cell differentiation.

Tumor necrosis factor, alpha-induced protein 2	Hs.525607	NM_006291	A cytokine mainly produced by macrophages causes apoptotic cell death, cellular proliferation, differentiation and inflammation.

TEK tyrosine kinase, endothelial	Hs.89640	NM_000459	Helps in vascular maturation, maintenance of integrity and remodeling.

Transforming growth factor, alpha	Hs.170009	NM_003236	Binds to EGFR and is involved in tumorigenesis.

Vascular endothelial growth factor C	Hs.435215	NM_005429	Involved in angiogenesis and lymphangiogenesis.


Original data	Secret data	XOR result

0	0	0

0	1	1

1	0	1

1	1	0


Studies	BCC +	SCC + (control)

Karahan, et al. [16]	20/20	0/20

Fan, et al. [28]	51/51	-

Krahl & Sellheyer [29]	28/28	-

Ishida, et al. [30]	20/20	-

Filho, et al. [31]	20/20	-

Mashhood, et al. [32]	29/29	0/11

Tan & Sunjaya [9]	23/23	-

Kirzhner & Jakobiec [33]	13/13	-

Dasgeb, et al. [24]	24/24	1/11 (weak positive)

Patil, et al. [12]	9/9	-

Sellheyer, et al. [34]	17/17	0/75

Ansai, et al. [35]	30/31	-

BerEP4 positive	284	1

Ber EP4 negative	1	116

Total	285	117

Sensitivity	284/285 × 100 = 99.6%

Specificity	116/117 × 100 = 99.2%

Positive predictive value	284/285 × 100 = 99.6%

Negative predictive value	116/117 × 100 = 99.1%

Studies

Karahan, et al. [16]

Fan, et al. [28]

Krahl & Sellheyer [29]

Ishida, et al. [30]

Filho, et al. [31]

Mashhood, et al. [32]

Tan & Sunjaya [9]

Kirzhner & Jakobiec [33]

Dasgeb, et al. [24]

Patil, et al. [12]

Sellheyer, et al. [34]

Ansai, et al. [35]

BerEP4 positive

Ber EP4 negative

Total

Sensitivity

Specificity

Positive predictive value

Negative predictive value


Code	Name	Classification algorithm(s) used

CAS	Chinese Academy of Sciences	Naïve Bayes, Support Vector Machine

CBC	CapitalBio Corporation, China	k-Nearest Neighbor, Support Vector Machine

Cornell	Weill Medical College of Cornell University	Support Vector Machine

FBK	Fondazione Bruno Kessler, Italy	Discriminant Analysis, Support Vector Machine

GeneGo	GeneGo, Inc.	Discriminant Analysis, Random Forest

GHI	Golden Helix, Inc.	Classification Tree

GSK	GlaxoSmithKline	Naïve Bayes

NCTR	National Center for Toxicological Research, FDA	k-Nearest Neighbor, Naïve Bayes, Support VectorMachine

NWU	Northwestern University	k-Nearest Neighbor, Classification Tree, Support VectorMachine

SAI	Systems Analytics, Inc.	Discriminant Analysis, k-Nearest Neighbor, Machine Learning,Support Vector Machine, Logistic Regression

SAS	SAS Institute, Inc.	Classification Tree, Discriminant Analysis, LogisticRegression, Partial Least Squares, Support VectorMachine

Tsinghua	Tsinghua University, China	Classification Tree, k-Nearest Neighbor, Recursive FeatureElimination, Support Vector Machine

UIUC	University of Illinois, Urbana-Champaign	Classification Tree, k-Nearest Neighbor, Naïve Bayes,Support Vector Machine

USM	University of Southern Mississippi	Artificial Neural Network, Naïve Bayes, SequentialMinimal Optimization, Support Vector Machine

ZJU	Zejiang University, China	k-Nearest Neighbor, Nearest Centroid


	Not at all	A little bit	Moderately	Quite a bit	Extremely	No/inappropriate answer	Total

	n	%	n	%	n	%	n	%	n	%	n	%	n	%

Any reminder brought back feelings about it	63	21.6	117	40.1	63	21.6	25	8.6	15	5.1	9	3.1	292	100

I had trouble staying asleep	206	70.5	37	12.7	28	9.6	8	2.7	1	0.3	12	4.1	292	100

Other things kept making me think about it	189	64.7	58	19.9	24	8.2	6	2.1	6	2.1	9	3.1	292	100

I felt irritable and angry	234	80.1	38	13.0	7	2.4	4	1.4	0	0.0	9	3.1	292	100

I avoided letting myself get upset when I thought about it or was reminded of it	145	49.7	91	31.2	24	8.2	17	5.8	5	1.7	10	3.4	292	100

I thought about it when I didn't mean to	133	45.5	100	34.2	31	10.6	14	4.8	3	1.0	11	3.8	292	100

I felt as if it hadn't happened or wasn't real	199	68.2	46	15.8	21	7.2	5	1.7	1	0.3	20	6.8	292	100

I stayed away from reminders about it	197	67.5	53	18.2	15	5.1	7	2.4	3	1.0	17	5.8	292	100

Pictures about it popped into my mind	193	66.1	59	20.2	14	4.8	8	2.7	3	1.0	15	5.1	292	100

I was jumpy and easily startled	172	58.9	63	21.6	24	8.2	11	3.8	9	3.1	13	4.5	292	100

I tried not to think about it	152	52.1	67	22.9	34	11.6	18	6.2	7	2.4	14	4.8	292	100

I was aware that I still had a lot of feelings about it,but I didn't deal with them	165	56.5	62	21.2	26	8.9	17	5.8	6	2.1	16	5.5	292	100

My feelings about it were kind of numb	162	55.5	70	24.0	35	12.0	6	2.1	2	0.7	17	5.8	292	100

I found myself acting or feeling as though I was back at that time	214	73.3	42	14.4	17	5.8	4	1.4	1	0.3	14	4.8	292	100

I had trouble falling asieep	212	72.6	38	13.0	14	4.8	10	3.4	4	1.4	14	4.8	292	100

I had waves of strong feelings about it	192	65.8	53	18.2	22	7.5	9	3.1	5	1.7	11	3.8	292	100

I tried to remove it from my memory	201	68.8	42	14.4	21	7.2	9	3.1	4	1.4	15	5.1	292	100

I had trouble concentrating	226	77.4	40	13.7	9	3.1	3	1.0	1	0.3	13	4.5	292	100

Reminders of it caused me to have physical reactions,such as sweating,trouble breathing,nausea,or a pounding heart	227	77.7	38	13.0	12	4.1	4	1.4	0	0.0	11	3.8	292	100

I had dreams about it	246	84.2	28	9.6	4	1.4	1	0.3	0	0.0	13	4.5	292	100

I felt watchful or on-guard	112	38.4	92	31.5	41	14.0	20	6.8	14	4.8	13	4.5	292	100

I tried not to talk about it	187	64.0	54	18.5	22	7.5	11	3.8	5	1.7	13	4.5	292	100


	Sample 1	Sample 2

Control Slide	41	52

Splashing device	29	34


Variable	OAK and controlpreinterventionb	OAK	Control	Difference in change between groups

		8weeks	6months	8weeks	6months	Preinterventionto 8 weeks	95%CI	Preintervention to 6 months	95% CI

TUG (score)c	12 (0)	10 (0.2)	10 (0.2)	11 (0.2)	11 (0.2)	-1.3	-1.81 to -0.86	-0.72	-1.35 to -0.08

Muscle Strength (kg)


Groups for Comparions	Dependent Variables	Degrees of freedom	Chi-square	p

Control (n=14)	TBARs (nmol/g)	3	3.87	0.28

STZ (n=12)	SOD (U/mg)	3	6.40	0.09

P+STZ (n=12)	CAT (K/g)	3	5.98	0.11

STZ+P (n=13)	GSH-Px (U/mg)	3	3.46	0.33


Scenario 4 - health, Work Cover & employment data linked by researchers

Consent justifications	No consent justifications

Consent provides protection against potential impact of research (10)a	Acceptable practice because of the benefits (5)

Access to identifiable data by researchers requires consent (9)	The findings are presented in de-identified form (3)

Practical considerations of obtaining consent from thousands (3)

Consent required when researchers do the linkage (7)	Acceptable due to cost and time constraints involved when obtaining consent (2)

Consent is required when other spheres of life (apart from health) are involved (7)	Consent lowers research participation rates (2)

Opt-out consent would result in more participants being involved (6)	Low participation rates impact on quality of research (2)

Consent required because of lack of separation of tasks (4)	The information is already there so it should just be used without consent (2)

People have right to choose (4)

Researchers may disclose information to third party (2)	Researchers are not interested in specific cases (2)

Someone on the research team may know the research participants (2)	Strict measures/guidelines provide protection (2)

To ensure people are not upset/do not object (2)	Getting consent could have detrimental effect on participants (1)

No need for consent if data linkage organisation is trustworthy (1)

Opt-in consent captures the people who really want to participate (2)	Researchers will not use information obtained without consent to harm participants (1)

Having the option to consent is good (2)

Information belongs to people (1)	Provided that the linkage organisation was involved so that tasks are separated (1)

People want to control their information (1)

Researchers using identifiable information without consent is intrusive (1)	Researchers will be dealing with de-identified data eventually (1)

Acceptable depending on study (1)

Consent required when participants are experiencing mental health issues, as they may not welcome people delving into their affairs at that point in their lives (1)	Consent would have been given at data collection point (1)

Information given to WorkCover can be shared with researchers, as it was given confidentially (1)

Consent should be sought for all research (1)	Retrospective use of data does not require consent (1)

Consent should be sought at initial point of data collection (1)	People have inflated view of how interesting they are to others (1)

Collecting this kind of information without consent may not be legal (1)

It is very good to obtain consent if it is simple to do so (1)

Scenario 4 - health, Work Cover & employment data linked by researchers

Consent justifications	No consent justifications

To ensure people are not upset/do not object (2)	No need for consent if data linkage organisation is trustworthy (1)

Opt-in consent captures the people who really want to participate (2)	Researchers will not use information obtained without consent to harm participants (1)

Having the option to consent is good (2)

Information belongs to people (1)	Provided that the linkage organisation was involved so that tasks are separated (1)

People want to control their information (1)

Researchers using identifiable information without consent is intrusive (1)	Researchers will be dealing with de-identified data eventually (1)

Acceptable depending on study (1)

Consent required when participants are experiencing mental health issues, as they may not welcome people delving into their affairs at that point in their lives (1)	Consent would have been given at data collection point (1)

Information given to WorkCover can be shared with researchers, as it was given confidentially (1)

Consent should be sought for all research (1)	Retrospective use of data does not require consent (1)

Consent should be sought at initial point of data collection (1)	People have inflated view of how interesting they are to others (1)

Collecting this kind of information without consent may not be legal (1)

It is very good to obtain consent if it is simple to do so (1)


Breed	Samples	GG	GA	AA	Freq. A	Exp GG	Exp GA	Exp AA

Abyssinian*	1955	1476	465	14	0.126	1493	431	31

Abyssinian (UK)	36	28	8	0	0.11	29	7	0

American Bobtail	10	10			0

American SH	51	51			0

American Wirehair	11	11			0

Australian Mist (UK)	27	27			0

Balinese	39	39			0

Bengal*	1340	925	390	25	0.164	936	368	36

Bengal (UK)	1210	827	354	29	0.17	834	341	35

Birman	187	187			0

British SH	966	966			0

British SH (UK)	43	43			0

Burmese	118	118			0


Demographic data and diagnoses	IPC + sevoflurane (N = 20)	IPC (N = 20)

Age (years)	68 ± 12	68 ± 11

Height (cm)	170 ± 11	170 ± 8

Weight (kg)	77 ± 17	75 ± 9

Male/female	14/6	13/7

Body-Mass-Index (BMI; kg.m-2)	27 ± 5	26 ± 3

Ankle-Brachial-Index (ABI)*	0.58 ± 0.18	0.56 ± 0.05

Side of surgery (right/left)	13 (65%)/7 (35%)	6 (30%)/14 (70%)

Fontaine grade (I/IIa/IIb/III/IV/V)	0/3/14/1/2 (0%/15%/70%/5%/10%)	0/5/14/0/1 (0%/25%/70%/0%/10%)

Obesity	5 (25%)	1 (5%)

Alcohol abuse	1 (5%)	1 (5%)

History of stroke	4 (20%)	1 (5%)

Diabetes mellitus	6 (30%)	5 (25%)

Hyperlipidaemia	14 (70%)	12 (60%)

Hypertonia	18 (90%)	17 (85%)

Hyperuricaemia	1 (5%)	5 (25%)

Coronary heart disease	9 (45%)	6 (30%)

Renal insufficiency	4 (20%)	1 (5%)

Smoking	9 (45%)	10 (50%)

Demographic data and diagnoses	IPC + sevoflurane (N = 20)	IPC (N = 20)

Ankle-Brachial-Index (ABI)*	0.58 ± 0.18	0.56 ± 0.05

Side of surgery (right/left)	13 (65%)/7 (35%)	6 (30%)/14 (70%)

Fontaine grade (I/IIa/IIb/III/IV/V)	0/3/14/1/2 (0%/15%/70%/5%/10%)	0/5/14/0/1 (0%/25%/70%/0%/10%)

Obesity	5 (25%)	1 (5%)

Alcohol abuse	1 (5%)	1 (5%)

History of stroke	4 (20%)	1 (5%)

Diabetes mellitus	6 (30%)	5 (25%)

Hyperlipidaemia	14 (70%)	12 (60%)

Hypertonia	18 (90%)	17 (85%)

Hyperuricaemia	1 (5%)	5 (25%)

Coronary heart disease	9 (45%)	6 (30%)

Renal insufficiency	4 (20%)	1 (5%)

Smoking	9 (45%)	10 (50%)


Characteristics of children	Number of children (%)	Mean per year/per team (min/max)	Median per year/per team (P25/P75)

Age of children

 0–1 y	885 (25%)

 1–10 y	1689 (47%)

 11–20 y	879 (24%)

 > 20 y	116 (3%)	144 (43–240)	144 (103–196)

Total of children: 3607 (100%)

Pathologies

 Haematology/Oncology	1816 (50%)

 Neurology-/Degenerative/Metabolic	989 (27%)

 Other (Neonatology/Gastroenterology/Respiratory)	849 (23%)

	Total: 3654 (100%)

Curative/Palliative Patients

 Curative patients	2540 (70%)	102 (1–181)	105 (82–135)

 Palliative patients	910 (25%)	36 (10–86)	23 (20–58)

 Undefined	157 (5%)

	Total: 3607 (100%)

Referral of new patients

 From originating hospital	1848 (51%)

 External hospital	108 (3%)

Total new patients	2056 (54%)

	Total: 3607 (100%)

Length follow-up (children who died)		226 days/child (1–4612 days)	32 days/child (21–201 days)

< 120 days	272 (64%)

 121–240 days	65 (15%)

 241–400 days	31 (7%)

> 401 days	60 (14%)

	Total: 428 (100%)

Location of death

 Hospital	200 (47%)	8 (2–22)	6 (6–10)

 Home	221 (51%)	9 (1–22)	9 (3–16)

 Others (respite care home, others)	7 (2%)	18 (3–32)	19 (12–26)

	Total: 428 (100%)

Characteristics of children	Number of children (%)	Mean per year/per team (min/max)	Median per year/per team (P25/P75)

Neurology-/Degenerative/Metabolic	989 (27%)

Other (Neonatology/Gastroenterology/Respiratory)	849 (23%)

	Total: 3654 (100%)

Curative/Palliative Patients

Curative patients	2540 (70%)	102 (1–181)	105 (82–135)

Palliative patients	910 (25%)	36 (10–86)	23 (20–58)

Undefined	157 (5%)

	Total: 3607 (100%)

Referral of new patients

From originating hospital	1848 (51%)

External hospital	108 (3%)

Total new patients	2056 (54%)

	Total: 3607 (100%)

Length follow-up (children who died)		226 days/child (1–4612 days)	32 days/child (21–201 days)

< 120 days	272 (64%)

121–240 days	65 (15%)

241–400 days	31 (7%)

> 401 days	60 (14%)

	Total: 428 (100%)

Location of death

Hospital	200 (47%)	8 (2–22)	6 (6–10)

Home	221 (51%)	9 (1–22)	9 (3–16)

Others (respite care home, others)	7 (2%)	18 (3–32)	19 (12–26)

	Total: 428 (100%)


Acoustic lens properties

Excitation center frequency [MHz]	100

Max PRF [kHz]	100

Gain [dB]	40

Sampling rate [MSamples/s]	400

Focal resolution [μm]	10

Aperture [μm]	950

Aperture angle [°]	55

Working distance [μm]	900


	N

Treatment interruption for reasons other than PD	5

Death for reason other than GBM	1

No measurable disease at time of randomization	6

No imaging available for central review	4

Total	16


Behaviors	Scores

1	2	3

Target: Cat touches a plastic chopstick or trainer’s finger with its nose	Stretching neck toward target	Purposeful movement towards target, but no touch; or touches with face but not nose	Actual contact with nose

Spin (in either direction): Cat turns body in a circle	Head follows or <90 degree turn	Spins approximately 91–270 degrees	Spins approximately 271–360 degrees

Sit: Cat assumes a sitting position, with hind-end on floor and front paws touching the floor, in a weight-bearing stance	Some hind-end crouching	Hind-end on floor or in close proximity and/or front paws go up	Front paws on floor and hind-end contact with floor

High-five: Cat touches a trainer’s hand with a front paw	Any degree of front paw lift (one or both paws)	Movement towards hand with just one paw	Purposeful hand contact with one paw


	Odds ratio (95 % confidence interval)	P-value

Age	1.0 (0.9–1.1)	0.11

Race

 African American	1.3 (0.6–3.0)	0.47

 Other	1.2 (0.7–2.3)	0.49

At least one previous prostate biopsy	0.7 (0.3–1.3)	0.26

Abnormal Digital Rectal Exam	30.5 (11.8–92.2)	<0.001

Family history of prostate cancer	3.5 (1.8–6.8)	<0.001

Prostate-specific antigen (ng/mL)a	4.4 (3.3–5.9)	<0.001

Sarcosine uM in 20uL seruma	1.1 (0.7–1.8)	0.64

	Odds ratio (95 % confidence interval)

Age	1.0 (0.9–1.1)

Race

African American	1.3 (0.6–3.0)

Other	1.2 (0.7–2.3)

At least one previous prostate biopsy	0.7 (0.3–1.3)

Abnormal Digital Rectal Exam	30.5 (11.8–92.2)

Family history of prostate cancer	3.5 (1.8–6.8)

Prostate-specific antigen (ng/mL)a	4.4 (3.3–5.9)

Sarcosine uM in 20uL seruma	1.1 (0.7–1.8)


	Intervention group	Control group

	Baseline (%)	End of study (%)	PValue	Baseline (%)	End of study (%)

Krece plus questionnaire

Breakfast	99.2	98.2	0.11	99.8	99.2

Dairy product at breakfast	91.9	92.3	0.72	95.4	93.0

Cereals at breakfast	68.3	72.9	0.01	74.8	74.5

Pastry at breakfast	17.5	15.3	0.17	16.2	15.1

Daily fruit or natural juice	70.9	72.9	0.30	78.1	78.9

Fruit, second per day	38.3	42.6	0.03	38.4	37.6

Dairy product, second per day	81.9	80.6	0.43	85.9	84.2

Vegetables, daily	68.9	72.6	0.04	72.7	73.8

Vegetables, >1 per day	25.7	32.0	0.001	23.2	26.9

Fish, regularly	73.9	74.8	0.65	76.10	74.3

Fast food, >1 per week	7.9	8.9	0.41	7.9	8.7

Legumes >1 per week	75.5	75.2	0.85	76.9	70.9

Candy >1 per day	12.9	12.0	0.52	11.6	9.9

Pasta or rice, daily	57.3	57.9	0.80	59.9	62.2

Cooking with olive oil at home	96.6	97.4	0.32	97.1	97.9

AVall questionnaire

Before leaving home

Dairy products	84.3	82.4	0.20	86.6	83.8

Pastry	3.9	2.4	0.005	2.8	2.6

Cereals	37.6	38.2	0.87	38.4	39.7

Fresh fruit or natural juice	20.9	20.6	0.07	18.8	18.5

Sandwich	23.9	25.2	0.45	19.1	22.1

Juice packaged/soft drinks	9.6	7.2	0.93	8.4	8.9

Break (Midmorning)

Dairy products	17.3	12.7	0.79	13.7	10.1

Pastry	3.8	1.7	<0.001	4.1	2.2

Cereals	6.5	5.6	0.68	5.2	4.7

Fresh fruit or natural juice	12.5	12.7	0.59	12.2	15.5

Sandwich	45.5	49.2	0.09	43.3	48.3

Juice packaged/soft drinks	11.4	6.1	0.67	9.9	12.8


Taxon, area, location	Code	N	Date	Coordinates

Clupea pallasii

NW Pacific & Bering Sea

 Sea of Japan	JAP	24	2005	48.40°N, 141.94°E

 Sea of Okhotsk, Taui Bay	OKH	37	5.2005	59.40°N, 150.12°E

 	 	 	31.8.2007	59.18°N, 149.05°E

 Bering Sea, Togiak Bay	BER	48	 	58°N, 160°W

NE Pacific

 Gulf of Alaska, Kodiak Bay	KOD	27	 	57°N, 154°W

 Washington	WAS	28	2009	48°N, 125°W

Pacific, Total	 	164

Pechora Sea

 Chesha Bay, Yarnei River	CHE	21	16.6.2010	67.78°N, 45.99°E

 Indiga Bay, near Svyatoi Nos	IND	21	20.6.2010	67.87°N, 48.58°E

White Sea

 Mezen Bay, West Kanin	MEZ	24	16.6.2010	67.20 N, 43.49 E

 Dvina Bay, Yandovaya Inlet	YAN	36+5	5.2001; 15.6.2010	64.66°N, 39.82°E

 Onega Bay, Kolezhma Inlet	KLZ	21	11.5.2001	64.30°N, 35.91°E

 Onega Bay, Kii Island	KIY	12	18.5.2001	64.00°N, 37.90°E

 Gulf of Kandalaksha, Chupa Inlet*	CHP	10	19.4.2001	66.30°N, 33.47°E

 Gulf of Kandalaksha, Chupa Inlet	CHU	23	30.8.1994	66.30°N, 33.47°E

 Gulf of Kandalaksha, Kolvitsa*	KOL	38	30.4.2010	67.04°N, 32.55°E

 Gulf of Kandalaksha, Umba	UMB	32	16.6.2010	66.65°N, 34.25°E

Norwegian Sea

 Balsfjord	BLS	39	28.4.2009	69.27°N, 19.28°E

European C. pallasii, Total	 	282

Clupea harengus

 NW Atlantic, Canada	CAN	26	10.3.2010	47°N, 47°E

 Norwegian Sea	NOR	26	2010	72°N, 16°E

 Baltic Sea, Bothnian Sea	BOT	30	2009	62°N, 19°E

Total C. harengus	 	85

Total, both species	 	528


Characteristic	Distribution

Sex [n (%)]

Female	117 (12%)

Male	848 (88%)

Age [mean (range)]	37 (18 – 67)

Transmission Risk Factor [n (%)]

MSM, not IDU	567 (59)

IDU	189 (20)

Heterosexual	160 (17)

Other/Unknown	49 (5)

Race/Ethnicity [n (%)]

Black	139 (14)

Hispanic	193 (20)

White	559 (58)

Other/Unknown	74 (8)

Prior Antiretroviral Treatment [n (%)]

Experienced	571 (59)

Naive	394 (41)

Absolute CD4 [mean (std dev)]	233 (337)

log10 HIV Plasma Viral Load [mean (std dev)]	4.6 (1.7)


Patients	Cancer classification	Clinical stage

1	Adenocarcinoma	cT2N + M0, Stage III

2	Adenocarcinoma	cT3N + M0, Stage III

3	Adenocarcinoma	cT3N + M0, Stage III

4	Adenocarcinoma	cT3N0M0, Stage II

5	Adenocarcinoma	cT3N + M0, Stage III

6	Adenocarcinoma	cT3N + M0, Stage III

7	Adenocarcinoma	cT3N + M0, Stage III

Patients	Cancer classification	Clinical stage

3	Adenocarcinoma	cT3N + M0, Stage III

4	Adenocarcinoma	cT3N0M0, Stage II

5	Adenocarcinoma	cT3N + M0, Stage III

6	Adenocarcinoma	cT3N + M0, Stage III

7	Adenocarcinoma	cT3N + M0, Stage III


Variable

Baseline

Insulin (pmol/L)

HOMA-IR

HOMA (β-cell)

Insulin, follow-up week (pmol/L)

1

2

3

4

5

6

8

9

12

Insulin (pmol/L) [n]

With DM1

Without DM2

P value (1 vs. 2)

HOMA-IR

With DM3

Without DM4

P value (3 vs.4)

HOMA- β-cell

With DM5

Without DM6

p value (5 vs.6)

MMII† pmol/L(%)

With DM [week]7

Without DM [week]8

p value (7 vs. 8)


NOPES score	≥1	≥2	≥3

Sensitivity (%)	98.7	68.9	24.3

Specificity (%)	14.1	59.2	95.1

Validity index (%)	38.4	62	74.8

Positive predictive value (%)	31.6	40.5	66.7

Negative predictive value (%)	96.3	82.6	75.8

Youden Index	0.13	0.28	0.19

Prevalence of BE (%)	31.6	40.8	66.7


Plant	Material	Shoot Weight	Lead Concentration	Lead Uptake

(a)	(b)	(c = a × b)

(mg box−1 DW)	(μg g−1 DW)	(μg box−1 DW)

Barley	+HAP	410 ± 90	7 ± 2	2.7 ± 0.2

−HAP	240 ± 40	90 ± 70	18 ± 13

p value		0.1513	0.2964	0.2867

Hairy vetch	+HAP	700 ± 100	9 ± 1	6.1 ± 1.2

−HAP	244 ± 24	24 ± 7	5.5 ± 1.3

p value		0.0014 **	0.1005	0.7530

Plant	Shoot Weight	Lead Concentration	Lead Uptake

(a)	(b)	(c = a × b)

(mg box−1 DW)	(μg g−1 DW)	(μg box−1 DW)

p value	0.0014 **	0.1005	0.7530


	Clinical Dosage	Flow Rate	Volume and Syringe Size

Loading Dose	4 g MgSO4 over 20 min	60 mL/h	20 mL in a single 20 mL syringe

Maintenance Dose	1 g/h MgSO4 for 24 h	5 mL/h	120 mL in two 60 mL syringes

Clinical Dosage	Flow Rate	Volume and Syringe Size

4 g MgSO4 over 20 min	60 mL/h	20 mL in a single 20 mL syringe

1 g/h MgSO4 for 24 h	5 mL/h	120 mL in two 60 mL syringes


	Direct	Indirect

Medical	Medical consultations (Ch-P)c	d

Skills training (Ch)

Parent training (P)

Day-care treatment (Ch)

Hospitalization (Ch)

Medication (Ch-P)

Non-medical	Remedial teaching at school (Ch)	Agency for child welfare (Ch)

Weekend care (Ch)	Police (Ch)

Care after school (Ch)	Special education (Ch)

Diet (Ch)	Productivity losses

	Absenteeism (P)

	Presenteeism (P)

	Direct	Indirect

Medical	Medical consultations (Ch-P)c	d

Skills training (Ch)

Parent training (P)

Day-care treatment (Ch)

Hospitalization (Ch)

Medication (Ch-P)

Non-me	Remedial teaching at school (Ch)	Agency for child welfare (Ch)

Weekend care (Ch)	Police (Ch)

Care after school (Ch)	Special education (Ch)

Diet (Ch)	Productivity losses

	Absentee


Attributes	Levels

Cervical cancer risk	0, 2, 4 in 1,000

Genital wart risk	0, 50, 100 in 1,000

Common side effect e.g. mild fever, little pain	2, 6, 10, 14 in 100

Costs for 3 doses of HPV vaccinea	0 Baht, 5,000 Baht, 10,000 Baht

Attributes	Levels

Cervical cancer risk	0, 2, 4 in 1,000

Genital wart risk	0, 50, 100 in 1,000

Common side effect e.g. mild fever, little pain	2, 6, 10, 14 in 100

Costs for 3 doses of HPV vacci	0 Baht, 5,000 Ba


Laparoscopic surgery	Preoperative intraabdominal adhesions evaluation scores	Success rate	χ2	P value	RR

LC (n = 118)	≤ 3 points, n = 62	96.8%(60/62)	59.70	0.001	3.38a

>3 points, n = 56	28.6%(16/56)

LCBDE+LC (n = 171)	≤ 3 points, n = 59	84.7%(50/59)	53.41	0.001	3.27b

>3 points, n = 112	25.9%(29/112)

Laparoscopic surgery	Preoperative intraabdominal adhesions evaluation scores	Success rate	χ2	P value

LC (n = 118)	≤ 3 points, n = 62	96.8%(60/62)	59.70	0.001

>3 points, n = 56	28.6%(16/56)

LCBDE+LC (n = 171)	≤ 3 points, n = 59	84.7%(50/59)	53.41	0.001

>3 points, n = 112	25.9%(29/112)


Variable	No. (%)

Age at admission (days)

 21–90	8,168 (42.7)

 91–180	5,819 (30.5)

 181–270	3,196 (16.7)

 271–365	1,926 (10.1)

Gestation (weeks)

 37 1/7–44	16,049 (84.0)

 34 1/7–37	2,035 (10.7)

 29 1/7–34	789 (4.1)

 25–29	236 (1.2)

Sex

 Male	11,277 (59.7)

 Female	7,832 (40.3)

Ethnicity

 Hispanic	12,373 (64.8)

 Non-Hispanic	6,393 (33.5)

 Unknown	343 (1.7)

Recorded respiratory/cardiac conditions of newborn

 Respiratory distress syndrome	609 (3.2)

 Bronchopulmonary dysplasia	85 (0.4)

 Pulmonary anomalies	63 (0.3)

 Any pulmonary disease	678 (3.6)

 Cardiac anomalies	505 (2.6)

Payment source

 MediCal	11,673 (61.1)

 Private insurance/HMO/PPO	6,670 (34.9)

 Other	766 (4.0)

Variable

Age at admission (days)

21–90

91–180

181–270

271–365

Gestation (weeks)

37 1/7–44

34 1/7–37

29 1/7–34

25–29

Sex

Male

Female

Ethnicity

Hispanic

Non-Hispanic

Unknown

Recorded respiratory/cardiac conditions of newborn

Respiratory distress syndrome

Bronchopulmonary dysplasia

Pulmonary anomalies

Any pulmonary disease

Cardiac anomalies

Payment source

MediCal

Private insurance/HMO/PPO

Other


	Both sexes - all age groups	Males - all age groups	Females - all age groups

Year	Mid-year population	Total deaths from 4 NCDsa	Death ratea	ASMR	Mid-year population	Total deaths from 4 NCDs	Death rate	ASMR	Mid-year population	Total deaths from 4 NCDs	Death rate	ASMR

2010	20,675,000	62,565	3.0	1.8	10,273,000	35,584	3.5	4.4	10,402,000	26,981	2.6	3.0


Procedure	Percent Agreeing quite or very important.

ACLS/CPR	91

Central Venous Catheter Insertion	93

Paracentesis	90

Endotracheal Intubation	89

Lumbar Puncture	89

Thoracentesis	87

Arterial access and blood gases	82

Ambulatory ECG	79

Cardioversion	77

Exercise Stress Testing	77

Hemodynamic Monitoring	76

Temporary Pacemaker Insertion	75

Mechanical Ventilation	75

Transthoracic Pacing	71

Arthrocentesis	70

Bone Marrow Aspiration and Biopsy	60

Chest Tube Insertion	58

Venipuncture	50


Variable	Frequency in complete baseline sample	Frequency in complete 1-year follow-up sample	Frequency at 1-year follow-up among those who had valid MVPA and travel mode data

	N (%)	N (%)	N (%)

Sex	n=2064	n=913	n=812

Boy	926	(45)	374	(41)	333	(41)

Girl	1,138	(55)	539	(59)	479	(59)

E	n=		n=79

Variable	Frequency in complete baseline sample	Frequency in complete 1-year follow-up sample	Frequency at 1-year follow-up among those who had valid MVPA and travel mode data

	N (%)	N (%)	N (%)

thnicity	1914	n=885	4

White	1841	(96)	857	(97)	770	(97)

Other	73	(4)	28	(3)	24	(3)

Urban/rural status	n=2023	n=902	n=802

Hamlet and isolated dwelling	142	(7)	73	(8)	67	(8)

Village	506	(25)	248	(28)	219	(27)

Town and fringe	575	(28)	275	(30)	244	(30)

Urban >10 k	800	(40)	306	(34)	272	(34)

Parent education status	n=1882	n=877	n=786

None	140	(7)	53	(6)	45	(6)

GCSE or equivalent	963	(51)	454	(52)	405	(51)

A-levels or equivalent	468	(25)	204	(23)	186	(24)

Degree or postgraduate degree	311	(17)	166	(19)	150	(19)

Travel mode	n=2053	n=913	n=812

Bicycle	189	(9)	73	(8)	59	(7)

Bus or train	127	(6)	62	(7)	57	(7)

Car	923	(45)	357	(39)	322	(40)

Foot	814	(40)	421	(46)	374	(46)


PATIENT	SIZE AND POSITION OF CHROMOSOME 15 DELETION	ADDITIONAL CHROMOSOME ABERRATION	SEX	CLEFT PALATE	HEART DEFECT	DEVELOPMENTAL DELAY	FACIES ANOMALIES	ADDITIONAL ABNORMALITIES

Present case	del(15)(q14) (submicroscopic, 1,6 Mb)	t(1;13)(p31.1;q13),t(3;19)(p23;p12), t(9;15)(p23;q14),t(14;18)(q22;p11.23)	M	+	-	+	+	-

Chen et al., 2008	del(15)(q14) (submicroscopic, 5,6 Mb)	-	M	+	VSD	+	+	Epilepsy; speech and language disorder

Brunetti-Pierri et al., 2008 case 1	del(15)(q14) (submicroscopic, 4,2 Mb)	-	M	+ (Bifid uvula)	+	+	+	Bilateral inguinal hernias, autistic spectrum behavior

Brunetti-Pierri et al., 2008 case 2	del(15)(q13-q14) (submicroscopic, 8,9 Mb)	-	F	-	+	+	+	Hypotonia,feeding difficulties

Erdogan et al., 2007	del(15)(q14) (submicroscopic, 5,3 Mb)	-	F	+	ASD	+	+	Low-set ears, OFC 3rd percentile

Galan et al., 1991	del(15)(q12-q14)	-	M	+ (Bifid uvula)	Pulmonary valve stenosis	+	+	Right cryptorchidism, hearing deficency

Tonk et al., 1995	del(15)(q12-q14)	-	M	+	VSD, PDA, ischemic cardiomyopathy	+	+	Large fontanelles, hearing deficency

Autio et al., 1988	del(15)(q13-q15)	-	M	+	ASD	+	+	Cryptorchidism, kidney defect, corpus callosum agenesis

Herva and Vuorinen, 1980	del(15)(q12-q14)	Mosaic with 46, XY	M	-	VSD, hypoplastic pulmonary artery, atretic tricuspid valve	Died at 7 days	+	Cryptorchidism

Pauli et al., 1983	del(15)(pter-q15)	del(11)(q25-qter)	M	+ (Bifid uvula)	VSD	+	+	Cryptorchidism, unilateral renal ptosis

Windpassinger et al., 2003	del(15)(pter-q14)	del(3)(qter)	M	-	Persistent foramen ovale, PDA	+	+	Cryptorchidism, clubfeet, strabismus

Kucerova et al., 1979	del(15)(pter-q15)	del(3)(pter-p25)	M	-	-	+	+	Cryptorchidism

Duckett and Roberts, 1981	del(15)(pter-q14or15)	Trisomy 13(pter-q32 or 33)	F	+ (Bifid uvula)	VSD, ASD, PDA, transposition of great vessels	Died at 14 hr	+	Microphthalmia, tracheo-oesophageal fistula

Ming et al., 1977	del(15)(pter-q21)	del(6)(q27-qter)	F	+	-	Died at 3 days	+	Microphthalmia

Schwartz et al., 1985	del(15)(pter-q14)	del(22)(pter-q13.2)	M	-	Coarctation of aorta, PDA	+	+	Cleft alveolar ridge, hydronephrosis

Matsumura et al., 2003	del(15)(pter-q14)	Trisomy 22q	M	-	PDA	+	+	Renal failure, cryptorchidism

PATIENT	SIZE AND POSITION OF CHROMOSOME 15 DELETION	ADDITIONAL CHROMOSOME ABERRATION	SEX

Present case	del(15)(q14) (submicroscopic, 1,6 Mb)	t(1;13)(p31.1;q13),t(3;19)(p23;p12), t(9;15)(p23;q14),t(14;18)(q22;p11.23)	M

Chen et al., 2008	del(15)(q14) (submicroscopic, 5,6 Mb)	-	M

Brunetti-Pierri et al., 2008 case 1	del(15)(q14) (submicroscopic, 4,2 Mb)	-	M

Brunetti-Pierri et al., 2008 case 2	del(15)(q13-q14) (submicroscopic, 8,9 Mb)	-	F

Erdogan et al., 2007	del(15)(q14) (submicroscopic, 5,3 Mb)	-	F

Galan et al., 1991	del(15)(q12-q14)	-	M

Tonk et al., 1995	del(15)(q12-q14)	-	M

Autio et al., 1988	del(15)(q13-q15)	-	M

Herva and Vuorinen, 1980	del(15)(q12-q14)	Mosaic with 46, XY	M

Pauli et al., 1983	del(15)(pter-q15)	del(11)(q25-qter)	M

Windpassinger et al., 2003	del(15)(pter-q14)	del(3)(qter)	M

Kucerova et al., 1979	del(15)(pter-q15)	del(3)(pter-p25)	M

Duckett and Roberts, 1981	del(15)(pter-q14or15)	Trisomy 13(pter-q32 or 33)	F

Ming et al., 1977	del(15)(pter-q21)	del(6)(q27-qter)	F

Schwartz et al., 1985	del(15)(pter-q14)	del(22)(pter-q13.2)	M

Matsumura et al., 2003	del(15)(pter-q14)	Trisomy 22q	M

CLEFT PALATE	HEART DEFECT	DEVELOPMENTAL DELAY	FACIES ANOMALIES	ADDITIONAL ABNORMALITIES

+	-	+	+	-

+	VSD	+	+	Epilepsy; speech and language disorder

+ (Bifid uvula)	+	+	+	Bilateral inguinal hernias, autistic spectrum behavior

-	+	+	+	Hypotonia,feeding difficulties

+	ASD	+	+	Low-set ears, OFC 3rd percentile

+ (Bifid uvula)	Pulmonary valve stenosis	+	+	Right cryptorchidism, hearing deficency

+	VSD, PDA, ischemic cardiomyopathy	+	+	Large fontanelles, hearing deficency

+	ASD	+	+	Cryptorchidism, kidney defect, corpus callosum agenesis

-	VSD, hypoplastic pulmonary artery, atretic tricuspid valve	Died at 7 days	+	Cryptorchidism

+ (Bifid uvula)	VSD	+	+	Cryptorchidism, unilateral renal ptosis

-	Persistent foramen ovale, PDA	+	+	Cryptorchidism, clubfeet, strabismus

-	-	+	+	Cryptorchidism

+ (Bifid uvula)	VSD, ASD, PDA, transposition of great vessels	Died at 14 hr	+	Microphthalmia, tracheo-oesophageal fistula

+	-	Died at 3 days	+	Microphthalmia

-	Coarctation of aorta, PDA	+	+	Cleft alveolar ridge, hydronephrosis

-	PDA	+	+	Renal failure, cryptorchidism


	Treatment-naïve (n = 42)

All adverse events, n (%)	18 (42.9)

Treatment-related, n (%)	11 (26.2)

Oculara	11 (26.2)

Ocular hyperemia	6 (14.3)

Dark circles under the eyes	0

Eye pruritus	1 (2.4)

Decreased lacrimation	1 (2.4)

Eye allergy	1 (2.4)

Ocular discomfort	1 (2.4)

Eye pain	1 (2.4)

Serious	0

Leading to discontinuation, n (%)	6 (14.3)


	Comfortable	Natural	Soothed

Forest area	4.00 ± 0.60	4.63 ± 0.63	3.63 ± 0.91

Urban area	0.13 ± 0.40	−2.00 ± 0.53	0.00 ± 0.53


Non-financial COI terms	n (%)

Personal relationship	29 (54)

Other	21 (39)

Non-financial COI	18 (33)

Professional	15 (28)

Academic competition	12 (22)

Personal opinion	10 (19)

Academic	9 (17)

Intellectual passion	9 (17)

Religious views	8 (15)

Political	8 (15)

Personal	8 (15)

Intellectual	7 (13)

Ideological	7 (13)

Competing loyalties	5 (9)

Advocacy groups/institutional advocacy	5 (9)

Institutional	3 (6)

Legal relationship	3 (6)

Governmental	1 (2)


Polymorphisms	Subgroup	Heterogeneity	Test of association

OR (95% CI)	P Value	Model	I2 (%)	P Value

Donor

rs1800469	Overall	0.56 (0.32-0.98)	0.04	F	10	0.34


P-value

Age

0.998

0.543

0.828

0.158

0.066

Occupation

0.291

0.056

0.998

0.061

Duration of illness

0.014*

Intra-operative finding

0.447

0.098

0.046*

0.035*

0.460

0.157

0.114

0.844

Intra-operative procedure done

0.041*

Adhesion release

0.020*

Manual Reduction

0.014*

Hospital stay

0.001*


Lambertian Scattering	Epidermis	Dermis	Veins	Phalanx	Proximal Phalanx	Digital Arteries

Reflectance	32%	26%	34%	47%	26%	53%

Transmittance	68%	74%	66%	53%	74%	47%

Lambertian Scattering	Epidermis	Dermis	Veins	Phalanx	Proximal Phalanx	Digital Arteries

Transmittance	68%	74%	66%	53%	74%	47%


	Mazabuka	Kafue

(Total = 273)	(Total = 361)

%	(n)	%	(n)	p-value

Sex of head of family

Male	84	(226)	92	(327)	0.003

Females	16	(43)	8	(30)

Age of caretaker (years)

<	1	(41	14	(5	0.96


Diagnosis	Number OFSO patients	First line OFSO	Salvage OFSO

Chronic frontal sinusitis	23	7/23 (30%)	16/23 (70%)

Frontal sinus mucocele	11	8/11 (72%)	3/11 (28%)

Total inflammatory frontal sinus disease patients	34	15/34 (44%)	19/34 (56%)

Diagnosis

Chronic frontal sinusitis

Frontal sinus mucocele

Total inflammatory frontal sinus disease patients


Systematic name or TIGR identifier	Description

Tc00.1047053506811.120	Hypothetical protein 1 (HYPO1)

UP|Q9NIQ8 (Q9NIQ8)	Mucin-like protein

UP|Q72DX6 (Q72DX6)	Sensor histidine kinase

UP|Q25325 (Q25325)	Heat shock protein 70-related protein

UP|Q7TPK7 (Q7TPK7)	Ac2-048

UP|Q9XY95 (Q9XY95)	Neurotrophin

UP|H2A_TRYCR (P35066)	Histone H2A

UP|RL29_DROME (Q24154)	60S ribosomal protein L29 (L43)

UP|RS6_LEIMA (Q9NE83)	40S ribosomal protein S6

PDB|1II2_A.0|17942708|	1II2_A Chain A, Crystal Structure Of Phosphoenolpyruvate Carboxykinase (Pepck)

UP|O48239 (O48239)	Cytochrome b (Fragment)

gb|L22334.1|TRBS3RRBN	5.8S ribosomal RNA, internal transcribed spacers 1–7, and 28S ribosomal RNA


Attributes	Format

Date	MM/DD/YY

Time	(H) H:MM (military time)

Count	Number of cars measured for the previous five minutes

Beginning event time	HH:MM:SS (military)

Ending event time	HH:MM:SS (military)

Away team	—

Game attendance	—

W/L score	—

Attributes

Date

Time

Count

Beginning event time

Ending event time

Away team

Game attendance

W/L score

Format

MM/DD/YY

(H) H:MM (military time)

Number of cars measured for the previous five minutes

HH:MM:SS (military)

HH:MM:SS (military)

—

—

—


		IE >10%	AI >10%

		Absent(n = 55)	Present(n = 14)	P	Absent(n = 48)	Present(n = 21)	P


	Total population (R2 = 0.69*)	Type 1 (R2 = 0.73*)	Type 2 (R2 = 0.66*)

Covariate	ß	p-value	ß	p-value	ß	p-value


Characteristic	Community level (n=32)	Patch level (n=62)

Communities in cattle corridor (percent)	59.7%	–

Perceived patch condition (percent)

 Bad		9.80%

 Average		42.70%

 Good		47.50%

Patch usage by community members (percent)	40%	30%

Area of communal grazing land (hectares)*	24	6

Grazing lands with use restrictions (percent)*		8.06%

Characteristic	Community level (n=32)	Patch level (n=62)

Area of communal grazing land (hectares)*	24	6

Grazing lands with use restrictions (percent)*		8.06%


Bentonite symbol	Grain size distribution, %

0.5–1 μm	1–5 μm	5–10 μm	10–50 μm	50–100 μm

BP2	2.6	9.3	17.4	31.8	38.9


Practice Visitor as:	Assessor	Expert/Educator	Facilitator	Interpreter

Whose role is:	External assessment against standards.	Knowledge and skill transfer.	Consensus building to achieve group view.	Helping practice teams decide what and how they would like to improve.

Based upon:	Historical competence.	Best practice.	A template for process.	Practice based issues.

Controlling:	Outcome.	Outcome and process.	Process.	Neither outcome nor process, simply participation.

Theoretical basis:	Systems.	Systems and organisational development.	Organisational development.	Complexity.

Examples:	Accreditation systems.	Outreach project to set up systems for chronic disease management.	Maturity Matrix.	Action research.

Practice Visitor as:	Assessor	Expert/Educator	Facilitator	Interpreter

Theoretical basis:	Systems.	Systems and organisational development.	Organisational development.	Complexity.

Examples:	Accreditation systems.	Outreach project to set up systems for chronic disease management.	Maturity Matrix.	Action research.


Component	Consumers (n = 347)	Non-consumers (n = 17,220)	p-value

Calories, kcal	2250 ± 652	2190 ± 11	n.s.3


	Fatigue factor:Eigenvalue=3.357% variance=30.52	DB factor:Eigenvalue=1.50% variance=13.62	RT:Eigenvalue=1.33% variance=12.14

Drive late at night	0.774

Drive after prolonged work	0.774

Drive for long periods	0.734

Drive when tired	0.638

Drive with a cold	0.470

Lapses of concentration		0.794

Speeding		0.747

Miss warning signs		0.687

Hostility to others		0.434

Risks at work			0.865

Risks outside work			0.860

	Fatigue factor:Eigenvalue=3.357% variance=30.52	DB factor:Eigenvalue=1.50% variance=13.62	RT:Eigenvalue=1.33% variance=12.14

Miss warning signs		0.687

Hostility to others		0.434

Risks at work			0.865

Risks outside work			0.860


Variable	Control factor	Coded value	Uncoded value

x1	Coating weigh gain	−0.6566	9.0302

x2	Duration of coating	0.5152	29.8176

x3	Amount of plasticizer	1	120


Pretreatments	Weighted average degree of polymerization

Untreated Solka-Floc cellulose (control)	1, 110

Dilute acid	260

Dilute acid/Fe2+	150


	Depressive disorders	Anxiety disorders

Hypertension (-)	Hypertension (+)	P-value	Hypertension (-)	Hypertension (+)	P-value

Total	89	6		67	11

Maternal age

< 35 years	32	4	0.29	49	6	0.14

≥ 35 years	57	2	Reference	18	5	Reference

Parity

Nulliparity	53	4	Reference	41	7	Reference

Multiparity	40	2	0.97	26	4	0.85

Medication

No	23	2	Reference	30	4	Reference

Yes	64	4	0.91	32	2	0.67

Self-interruption	2	0	0.32 and 0.23*	5	5	0.03 and < 0.01*

Economic problems

No	85	6	Reference	56	10	Reference

Yes	4	0	0.6	11	1	0.87

	Depressive disorders	Anxiety disorders

Hypertension (-)	Hypertension (+)	P-value	Hypertension (-)	Hypertension (+)	P-value

Medication

No	23	2	Reference	30	4	Reference

Yes	64	4	0.91	32	2	0.67

Self-interruption	2	0	0.32 and 0.23*	5	5	0.03 and < 0.01*

Economic problems

No	85	6	Reference	56	10	Reference

Yes	4	0	0.6	11	1	0.87


		Number of Cancer Patients Treated2

Study Site	Total PopulationService Area1	Breast	Colorectal	Prostate	Lung	Other	TOTAL

Billings Clinic, Montana	283,828	186	133	207	150	753	1,429

Christiana Hospital, Delaware	571,322	533	258	367	447	1258	2,863

Hartford Hospital, Connecticut	1,054,456	544	217	479	280	1075	2,595

Our Lady of the Lake Regional Medical Center, Louisiana	672,319	362	250	365	539	1075	2,591

St. Joseph's/Candler, Georgia	385,242	227	124	87	253	366	1,057

St. Joseph's, Orange, California	2,432,932	385	147	118	149	728	1,527

Sanford USD Medical Center, South Dakota	489,576	187	147	139	177	586	1,236

Spartanburg Regional Hospital, South Carolina	353,757	244	136	193	253	553	1,379

Ascension Health, based in Missouri: St. Vincent Indianapolis Hospital, Indianapolis, Indiana	1,951,252	573	219	182	287	1934	3,195

Columbia St. Mary's Hospital, Milwaukee Wisconsin	685,066	417	157	227	169	692	1,662

Seton Family of Hospitals, Austin, Texas	1,544,670	371	171	58	300	1132	2,032

Catholic Health Initiatives, based in Colorado: Penrose-St. Francis Health Services, Colorado Springs, Colorado	477,263	208	156	197	110	552	1,223

St. Joseph Medical Center, Towson, Maryland	633,814	205	128	155	124	463	1,078

CHI Nebraska coordinated regional program: Good Samaritan Hospital, Kearney, Nebraska	205,994	87	67	95	77	227	553

St. Elizabeth Regional Medical Center, Lincoln, Nebraska	256,939	215	114	39	87	317	772

St. Francis Medical Center, Grand Island, Nebraska	106,724	104	106	82	59	208	559

TOTAL	12,105,154	4848	2530	2990	3461	11919	25,751

		Number of Cancer Patients Treated2

Study Site	Total PopulationService Area1	Breast	Colorectal	Prostate	Lung	Other

Billings Clinic, Montana	283,828	186	133	207	150	753

Christiana Hospital, Delaware	571,322	533	258	367	447	1258

Hartford Hospital, Connecticut	1,054,456	544	217	479	280	1075

Our Lady of the Lake Regional Medical Center, Louisiana	672,319	362	250	365	539	1075

St. Joseph's/Candler, Georgia	385,242	227	124	87	253	366

St. Joseph's, Orange, California	2,432,932	385	147	118	149	728

Sanford USD Medical Center, South Dakota	489,576	187	147	139	177	586

Spartanburg Regional Hospital, South Carolina	353,757	244	136	193	253	553

Ascension Health, based in Missouri: St. Vincent Indianapolis Hospital, Indianapolis, Indiana	1,951,252	573	219	182	287	1934

Columbia St. Mary's Hospital, Milwaukee Wisconsin	685,066	417	157	227	169	692

Seton Family of Hospitals, Austin, Texas	1,544,670	371	171	58	300	1132

Catholic Health Initiatives, based in Colorado: Penrose-St. Francis Health Services, Colorado Springs, Colorado	477,263	208	156	197	110	552

St. Joseph Medical Center, Towson, Maryland	633,814	205	128	155	124	463

CHI Nebraska coordinated regional program: Good Samaritan Hospital, Kearney, Nebraska	205,994	87	67	95	77	227

St. Elizabeth Regional Medical Center, Lincoln, Nebraska	256,939	215	114	39	87	317

St. Francis Medical Center, Grand Island, Nebraska	106,724	104	106	82	59	208

TOTAL	12,105,154	4848	2530	2990	3461	11919


	Low blood pressure criteria

SBP < 110 mmHg	SBP < 100 mmHg	SBP < 95 mmHg	SBP < 90 mmHg

Odds ratio (95% CI)


Species	Year	Captures	Odds ratio of capture on pipeline

On pipeline	Off pipeline

D. ordii	1997	35	106	1.663

1998	57	116	2.473

1999–2001	21	21	5.037

P. flavescens	1997	0	27	0

1998	5	44	0.572

1999–2001	13	75	0.873


Variable	Frequency (%)

Sex

Male	138 (76.7)

Female	42 (23.3)

Age (years)

< 10	1


Variables	Rs2910164 (Cases/Controls)	Crude OR (95% CI)	P	Adjusted ORa (95% CI)	Pa

CC	CG/GG

N	%	N	%

Age,


Treatment	N	Mean survival ± SE	95% CI

Nonsurgical	533	67 ± 3 months	62–72

Surgical	751	87 ± 4 months	80–95

Overall	1284	83 ± 3 months	78–88


Parasite density	Sample size (n)	Positives	Detection rate

<200	16	14	87.50%

200-1999	77	76	98.70%


DDS	SDDS

Food group	Note	Food group	Note

All starch staples	With a threshold of 10 g	Refined grains and cereals	With a threshold of 10 g

	Other cereals and grains	With a threshold of 10 g

	Starch tubers and roots	With a threshold of 10 g

Vitamin A-rich vegetables & fruit	With a threshold of 10 g	Vitamin A-rich dark-green leafy vegetables	With a threshold of 10 g

	Vitamin A-rich deep yellow/orange/red vegetables	With a threshold of 10 g

	Vitamin A-rich fruits	With a threshold of 10 g

All other fruits	With a threshold of 10 g	Vitamin C-rich vegetables	With a threshold of 10 g

All other vegetables	With a threshold of 10 g	Vitamin C-rich fruits	With a threshold of 10 g

		All other fruits & vegetables	With a threshold of 10 g

All legumes & nuts	With a threshold of 10 g	All legumes & nuts	With a threshold of 10 g

Oil and fat	With a threshold of 2 g	Oil and fat	With a threshold of 2 g

Meat, poultry, fish	With a threshold of 10 g	Meat, poultry, fish	With a threshold of 10 g

	Organ meat	With a threshold of 10 g

All dairy	With a threshold of 10 g	All dairy	With a threshold of 10 g

Eggs	With a threshold of 10 g	Eggs	With a threshold of 10 g

Other food	Exclude calculation	Desserts, candy, sugar-sweetened beverages and Puffing Food	With a threshold of 10 g

	Other food	With a threshold of 10 g


 	Estimated effect on baseline physical activity (minutes per day)	Estimated effect on physical activity trajectories (minutes per day per semester)

 	Fixed effect	P value	Fixed Effect	P value

Student Characteristics

Gender

 Female	−12.5 (2.04)	<0.0001	0.596 (0.598)	0.3194

 Male	Referent	 	Referent

Baseline physical activity

 Low	−47.7 (1.50)	<0.0001	7.11 (0.707)	<0.0001

 Moderate	−25.8 (1.51) 	<0.0001	4.20 (0.719)	<0.0001

 High	Referent	 	Referent

BMI status

 Overweight or obese	1.92 (3.21)	0.5512	−0.785 (0.901)	0.3894

 Healthy weight	Referent	 	Referent

 Missing	1.88 (2.35)	0.4252	−0.0527 (0.657)	0.9362

School neighbourhood characteristics

School location

 Rural	−10.6 (2.25)	<0.0001	1.49 (0.658)	0.0234

 Urban	Referent	 	Referent

Socioeconomic status

 Low	−9.09 (2.27)	<0.0001	1.75 (0.664)	0.0086

 High	Referent	 	Referent

	Estimated effect on baseline physical activity (minutes per day)	Estimated effect on physical activity trajectories (minutes per day per semester)

	Fixed effect	P value	Fixed Effect	P value

Student Characteristics

Gender

Fema	−12.5 	<	0.596	0.3194

le	(2.04)	0.0001	 (0.598)

Male	Referent		Referent

Baseline physical activity

Low	−47.7 (1.50)	<0.0001	7.11 (0.707)	<0.0001

Moderate	−25.8 (1.51)	<0.0001	4.20 (0.719)	<0.0001

High	Referent		Referent

BMI status

Overweight or obese	1.92 (3.21)	0.5512	−0.785 (0.901)	0.3894

Healthy weight	Referent		Referent

Missing	1.88 (2.35)	0.4252	−0.0527 (0.657)	0.9362

School neighbourhood characteristics

School location

Rural	−10.6 (2.25)	<0.0001	1.49 (0.658)	0.0234

Urban	Referent		Referent

Socioeconomic status

Low	−9.09 (2.27)	<0.0001	1.75 (0.664)	0.0086

High	Referent		Referent